

# 2024

19-21 GIUGNO ROMA

UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE -  
CENTRO CONGRESSI  
EUROPA



16° CONGRESSO NAZIONALE

# ICAR

Italian Conference on AIDS and  
Antiviral Research



RESEARCH and CARE: FROM BENCH,  
TO BEDSIDE, TO COMMUNITY



**Presidenza del Congresso**

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

## 16° Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research Research and care: from bench, to bedside, to community Roma, 19-21 Giugno 2024

Sito: [www.icar2024.it](http://www.icar2024.it)

**Presidenza del Congresso:**

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G.C. Marchetti, Milano

**ID ECM:**

Congresso (19 giugno: 150-408094, 20 giugno: 150-408149, 21 giugno: 150-408164)

**Destinatari dell'evento formativo**

Professione	Discipline
ASSISTENTE SANITARIO	ASSISTENTE SANITARIO
BIOLOGO	BIOLOGO;
EDUCATORE PROFESSIONALE	EDUCATORE PROFESSIONALE
FARMACISTA	FARMACISTA PUBBLICO DEL SSN
INFERMIERE	INFERMIERE
MEDICO CHIRURGO	ALLERGOLOGIA ED IMMUNOLOGIA CLINICA; ANGIOLOGIA; CARDIOLOGIA; DERMATOLOGIA E VENEREOLOGIA; EMATOLOGIA; ENDOCRINOLOGIA; GASTROENTEROLOGIA; GENETICA MEDICA; GERIATRIA; MALATTIE METABOLICHE E DIABETOLOGIA; MALATTIE DELL'APPARATO RESPIRATORIO; MALATTIE INFETTIVE; MEDICINA E CHIRURGIA DI ACCETTAZIONE E DI URGENZA; MEDICINA FISICA E

**Provider e Segreteria Organizzativa**

Effetti srl Via G.B. Giorgini 16 - 20151 Milano Phone +39 02 3343281 Fax +39 02 38002105 [icar@effetti.it](mailto:icar@effetti.it) [www.icar2024.it](http://www.icar2024.it)



19-21 GIUGNO ROMA

UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE -  
CENTRO CONGRESSI  
EUROPA



16° CONGRESSO NAZIONALE



Italian Conference on AIDS and  
Antiviral Research



RESEARCH and CARE: FROM BENCH,  
TO BEDSIDE, TO COMMUNITY



**Presidenza del Congresso**

- A. Cingolani, Roma
- A. Di Biagio, Genova
- M. Farinella, Roma
- G. C. Marchetti, Milano

	<p>RIABILITAZIONE; MEDICINA INTERNA; MEDICINA TERMALÉ;          MEDICINA AERONAUTICA E SPAZIALE; MEDICINA DELLO SPORT;          NEFROLOGIA; NEONATOLOGIA; NEUROLOGIA; NEUROPSICHIATRIA          INFANTILE; ONCOLOGIA; PEDIATRIA; PSICHIATRIA; RADIOTERAPIA;          REUMATOLOGIA; CARDIOCHIRURGIA; CHIRURGIA GENERALE;          CHIRURGIA MAXILLO-FACCIALE; CHIRURGIA PEDIATRICA;          CHIRURGIA PLASTICA E RICOSTRUTTIVA; CHIRURGIA TORACICA;          CHIRURGIA VASCOLARE; GINECOLOGIA E OSTETRICA;          NEUROCHIRURGIA; OFTALMOLOGIA; ORTOPEDIA E          TRAUMATOLOGIA; OTORINOLARINGOIATRIA; UROLOGIA;          ANATOMIA PATOLOGICA; ANESTESIA E RIANIMAZIONE;          BIOCHIMICA CLINICA; FARMACOLOGIA E TOSSICOLOGIA CLINICA;          LABORATORIO DI GENETICA MEDICA; MEDICINA TRASFUSIONALE;          MEDICINA LEGALE; MEDICINA NUCLEARE; MICROBIOLOGIA E          VIROLOGIA; NEUROFISIOPATOLOGIA; NEURORADIOLOGIA;          PATOLOGIA CLINICA (LABORATORIO DI ANALISI CHIMICO-CLINICHE          E MICROBIOLOGIA); RADIODIAGNOSTICA; IGIENE, EPIDEMIOLOGIA          E SANITÀ PUBBLICA; IGIENE DEGLI ALIMENTI E DELLA NUTRIZIONE;          MEDICINA DEL LAVORO E SICUREZZA DEGLI AMBIENTI DI LAVORO;          MEDICINA GENERALE (MEDICI DI FAMIGLIA); CONTINUITÀ          ASSISTENZIALE; PEDIATRIA (PEDIATRI DI LIBERA SCELTA); SCIENZA          DELL'ALIMENTAZIONE E DIETETICA; DIREZIONE MEDICA DI          PRESIDIO OSPEDALIERO; ORGANIZZAZIONE DEI SERVIZI SANITARI DI          BASE; AUDIOLOGIA E FONIATRIA; PSICOTERAPIA; CURE PALLIATIVE;          EPIDEMIOLOGIA; MEDICINA DI COMUNITÀ; MEDICINA SUBACQUEA          E IPERBARICA</p>
PSICOLOGO	PSICOTERAPIA; PSICOLOGIA
TECNICO SANITARIO LABORATORIO BIOMEDICO	TECNICO SANITARIO LABORATORIO BIOMEDICO

**ID ECM Corsi precongressuali**

Immune response in viral infections: where we are with new knowledge: **150-408048**

Addressing Viral Persistence Today and Tomorrow: **150-4080774**

Complexities of HIV management: when the going gets tough... the tough get going!: **150-408080**

Ageing in people with HIV: a feasible challenge: **150-408085**

# 2024

19-21 GIUGNO ROMA

UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE -  
CENTRO CONGRESSI  
EUROPA



16° CONGRESSO NAZIONALE

# ICAR

Italian Conference on AIDS and  
Antiviral Research



RESEARCH and CARE: FROM BENCH,  
TO BEDSIDE, TO COMMUNITY



#### Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

#### Promosso da SIMIT, Società Italiana di Malattie Infettive e Tropicali

e da

- **INMI**, Istituto Nazionale per le Malattie Infettive
- **ISS**, Istituto Superiore di Sanità
- **AMCLI**, Associazione Microbiologi Clinici Italiani
- **SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
- **SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
- **SITA**, Società italiana per la Terapia Antinfettiva
- **SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology
- **ANLAIDS**, Associazione Nazionale per la lotta all'AIDS
- **ARCIGAY**, Associazione LGBT Italiana
- **ARCOBALENO Aids ODV**, Associazione ARCOBALENO Aids ODV
- **ASA Onlus**, Associazione Solidarietà AIDS Onlus
- **C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS
- **EpaC Onlus**, Associazione EpaC Onlus
- **LILA**, Lega Italiana per la lotta contro l'AIDS
- **MARIO MIELI**, Circolo di Cultura Omosessuale
- **Milano Check Point**, Associazione Milano Check Point
- **NADIR**, Associazione Nadir
- **NPS Italia Onlus**, Network Persone Sieropositive
- **PLUS**, Rete persone LGBT+ sieropositive Aps

#### Razionale

**ICAR (Italian Conference on AIDS and Antiviral Research)**, ideata nel 2009 per far convergere e discutere le migliori iniziative in campo scientifico e di ricerca medica all'interno di un'unica conferenza a cadenza annuale, è la più importante occasione di incontro scientifico del nostro paese in tema di HIV e altre infezioni virali delle infezioni batteriche o fungine nel paziente immunocompromesso. Ogni anno ICAR riunisce oltre 1.000 tra specialisti e ricercatori, personale sanitario non-medico e volontari delle Associazioni dei Pazienti.

Promosso da **SIMIT** (Società Italiana di Malattie Infettive e Tropicali), con il patrocinio di tutte le maggiori società scientifiche del settore, le Istituzioni, la Community delle Associazioni Pazienti, ICAR 2024 - in programma a Roma dal 19 al 21 Giugno presso l'Università Cattolica del Sacro Cuore (Centro Congressi

# 2024

19-21 GIUGNO ROMA

UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE -  
CENTRO CONGRESSI  
EUROPA



16° CONGRESSO NAZIONALE

# ICAR

Italian Conference on AIDS and  
Antiviral Research



RESEARCH and CARE: FROM BENCH,  
TO BEDSIDE, TO COMMUNITY



#### Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

Europa) – è presieduto da Antonella Cingolani, Antonio Di Biagio, Massimo Farinella e Giulia Carla Marchetti, coadiuvati dalla Segreteria Scientifica e dagli Organi di Governo ICAR.

***“Research and care: from bench, to bedside, to community”*** è il claim che sostiene la 16° edizione del Congresso e che caratterizzerà il programma scientifico, promuovendo la riflessione sull’importanza della ricerca per raggiungere il prendersi cura in senso globale della persona.

Riteniamo che il prendersi cura della persona con HIV necessiti di una sinergia tra ricerca di base, ricerca clinica e costante interazione bidirezionale con la comunità di persone che vivono con HIV. Crediamo che questo garantisca una visione della ricerca sempre strettamente legata alla clinica con l’obiettivo di migliorare la vita delle persone che vivono con HIV.

Inoltre, l’emergenza di nuove infezioni a trasmissione sessuale, la disponibilità di molecole, strategie terapeutiche e di prevenzione innovative, consentiranno di ampliare il programma verso nuove sfide scientifiche proiettate verso un futuro estremamente stimolante.

Nelle tre giornate congressuali - caratterizzate da un approccio abstract-driven - i temi HIV/AIDS, SARS-CoV-2, epatiti, infezioni sessualmente trasmesse, virus emergenti e/o riemergenti, vaccini, infezioni nell’immunocompromesso, saranno al centro del dibattito scientifico.

#### **Oral Communications, Short Communications e Themed Discussion**

Come ogni Congresso Nazionale abstract-driven, le Oral Communications, Short Communications e Themed Discussion verranno selezionate dalla Segreteria Scientifica del Congresso sulla base della qualità scientifica degli abstract pervenuti solo dopo attenta analisi e valutazione degli stessi (che avverrà entro il 20 Maggio 2024).

Anche quest’anno, ICAR si rivolge ai giovani per ascoltarne la voce attraverso la decima edizione del **Concorso RaccontART** – il contest artistico promosso tra gli studenti delle scuole superiori – e, in tema di sanità pubblica, ICAR 2024 affronterà i problemi connessi alla cura ed alla prevenzione delle infezioni virali aprendosi alla società civile con l’offerta del **Test rapido HIV, HCV e sifilide** per la popolazione residente.

Il **Programma scientifico ICAR 2024** si sviluppa nel corso di tre giornate di lavoro, attraverso 4 Corsi pregressuali, una Opening Session Istituzionale, Keynote Lectures, Simposi Scientifici, Expert

# 2024

19-21 GIUGNO ROMA

UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE -  
CENTRO CONGRESSI  
EUROPA



16° CONGRESSO NAZIONALE

# ICAR

Italian Conference on AIDS and  
Antiviral Research



RESEARCH and CARE: FROM BENCH,  
TO BEDSIDE, TO COMMUNITY



**Presidenza del Congresso**

**A. Cingolani**, Roma

**A. Di Biagio**, Genova

**M. Farinella**, Roma

**G. C. Marchetti**, Milano

Meeting, Sessioni di Oral Communications, Short Communications e Themed Discussion, sulla base dei seguenti **main topics** che corrispondono alle Abstract Tracks del Congresso:

- **Antiretroviral therapy**
- **Clinical HIV**
- **Cooperation projects in low income countries**
- **Epidemiology of viral infections**
- **HIV coinfections and comorbidities**
- **Immunopathogenesis**
- **Other infections in the immunocompromised host**
- **SARS-CoV-2 infection and long COVID**
- **Sexually transmitted infections**
- **Social and behavioural science, marginalized groups, community aspects and community surveys**
- **Testing, prevention and PrEP: clinical perspectives and community best practice**
- **Vaccines**
- **Viral hepatitis**
- **Virology and pharmacology**

# 2024

19-21 GIUGNO ROMA

UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE -  
CENTRO CONGRESSI  
EUROPA



16° CONGRESSO NAZIONALE

# ICAR

Italian Conference on AIDS and  
Antiviral Research



RESEARCH and CARE: FROM BENCH,  
TO BEDSIDE, TO COMMUNITY



## Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

## Comitato Scientifico

### Segreteria Scientifica

Chiara Agrati, Roma – Mara Biasin, Milano – Paolo Bonfanti, Monza – Andrea Calcagno, Torino – Giulia Valeria Calvino, Roma – Antonella Castagna, Milano – Annamaria Cattelan, Padova – Francesca Ceccherini Silberstein, Roma – Maurizio Benedetto Celesia, Catania – Paola Maria Cinque, Milano – Nicola Coppola, Napoli – Gabriella d'Ettore, Roma – Simona Di Giambenedetto, Roma – Nicoletta Frattini, Milano – Anna Maria Geretti, Roma – Cristina Gervasoni, Milano – Enrico Girardi, Roma – Giovanni Guaraldi, Modena – Miriam Lichtner, Latina – Sergio Lo Caputo, Foggia – Giordano Madeddu, Sassari – Paolo Maggi, Caserta – Ada Moznich, Milano – Valentina Mazzotta, Roma – Silvia Nozza, Milano – Ilenia Pennini, Padova – Stefano Rusconi, Legnano MI – Maria Santoro, Roma – Annalisa Saracino, Bari – Loredana Sarmati, Roma – Barbara Sulgoi, Roma – Valentina Svicher, Roma – Lucia Taramasso, Genova – Camilla Tincati, Milano – Daria Lucia Trabattoni, Milano – Alessandra Vergori, Roma – Maurizio Zazzi, Siena

### Coordinatore Abstract

Antonio Di Biagio, Genova

### Segreteria Corsi pregressuali

Claudia Alteri, Milano – Francesca Bai, Milano – Eleonora Cimini, Roma – Giusi Giupponi, Como – Stefania Piconi, Lecco – Carmela Pinnetti, Roma – Carolina Scagnolari, Roma – Nicola Squillace, Monza

### Comitato Annuale di Programma (CAP)

Massimo Andreoni, Roma – Andrea Antinori, Roma – Antonella Castagna, Milano – Annamaria Cattelan, Padova – Salvatore Cecere, Bologna – Antonella Cingolani, Roma – Antonio Di Biagio, Genova – Massimo Farinella, Roma – Franco Maggiolo, Fabriano TR – Giulia Carla Marchetti, Milano – Paolo Meli, Bergamo – Cristina Mussini, Modena – Roberto Parrella, Napoli – Carlo Torti, Roma – Maurizio Zazzi, Siena

### Provider e Segreteria Organizzativa

Effetti Srl – 20151 Milano

Via G. B. Giorgini, 16

e-mail: [ICAR@effetti.it](mailto:ICAR@effetti.it)

https: [www.icar2024.it](https://www.icar2024.it)

#ICAR2024



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Wednesday, June 19

15:00 - 17:30

**Aula Bausola**

>>> Pre-Conference advanced course

### Immune response in viral infections: where we are with new knowledge

In the host, innate and adaptive immunity are the arms of a functional and well-organized immune response against several pathogens. Beside immune system, inflammation protects the host by eliminating pathogens, repairing damaged tissue, and restoring homeostasis. Inflammasome is the core component of the inflammatory response, having a crucial role in resisting pathogenic infections and maintaining immune homeostasis by releasing inflammatory soluble factors. An overactive inflammasome can also trigger a cytokine storm, leading to various inflammatory diseases and exacerbating tissue damage. During viral infections, a balanced immune/inflammatory response is prominent in resolving the infection. Innate immunity implements non cellular/cellular strategies to eliminate viruses in the early stage of infection, by priming specific T and B cells responses in the resolving phase. Viruses are able to modify host's immune response both in acute/chronic phases of infection, by evolving mechanisms to evade or to hyperactivate immune response by damaging the host. T cells have a pivotal role in controlling infectious diseases and cancer. Chimeric antigen receptor T-cells (CAR-T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Thus, it seems likely that engineered, re-directed T cells will also be able to control these diseases when naturally occurring T cells fail. A successful effector CAR-T cell therapy is designed to kill every cancer or virus-infected cell in the patient. By understanding the biology of naturally occurring T cells, these advances will help the field to engineer better T cells to function in a wide array of disease areas. In this pre-congress course we will deepen the innovative diagnostic and therapeutic aspects in the control of acute and chronic viral infections in view of the clinical and pathogenetic relevance of the host's immune response during viral infections.

#### Chairs: Eleonora Cimini (Roma), Stefania Piconi (Lecco)

15.00 - 15.30	<b>Innate immunity and inflammation</b>	<i>Roberta Rovito, Milano</i>
15.30 - 16.00	<b>Adaptive immune response in viral infections: T and B lymphocytes</b>	<i>Sara De Biasi, Modena</i>
16.00 - 16.30	<b>Monoclonal antibodies in viral infections</b>	<i>Emanuele Andreano, Siena</i>
16.30 - 17.00	<b>Novel T-cell therapies in viral infections</b>	<i>Veronica Bordoni, Roma</i>
17.00 - 17.30	<b>Discussion</b>	



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Wednesday, June 19

15:00 - 17:30

**Aula 5**

>>> Pre-Conference advanced course

### Addressing Viral Persistence Today and Tomorrow

The last decade has seen a profound change in our understanding of viral persistence as a much more dynamic picture of the reservoir emerged. The mechanisms that prevent HIV and HBV eradication have been redefined, as well as their role in chronic immune activation and inflammation. At the same time, the COVID-19 global pandemic caused by the SARS-CoV-2 reopens questions about the ability of some RNA viruses to drive chronic symptoms by persisting in certain body sites or tissue reservoirs after acute infection. In summary, viral persistence is undoubtedly complex and multifaceted process, but if approached from the right angle, can yield many clues for the identification of new weapons and new curative strategies to counteract it. Thus, this course is shedding light on the state of the art as well as the most recent discoveries and fascinating innovations in HIV, HBV, HDV persistence and post-COVID-19 syndrome. It uncovers putative links between viral persistence, viral evolution, host immune status, and protective immunity to guide and direct future basic science and clinical research priorities.

**Chairs: Claudia Alteri (Milano), Carolina Scagnolari (Roma)**

#### HIV-1: markers for persistence, latency and resistance

15.00 - 15.20 The virological point of view

*Ombretta Turriziani, Roma*

15.20 - 15.40 The clinical point of view

*Marco Iannetta, Roma*

15.40 - 15.50 Discussion

#### HBV/HDV: from virology to pathophysiology

15.50 - 16.10 The virological point of view

*Romina Salpini, Roma*

16.10 - 16.30 The clinical point of view

*Elisabetta Degasperi, Milano*

16.30 - 16.40 Discussion

#### SARS-CoV-2: evolution and monitoring

16.40 - 17.00 The virological point of view

*Alessandra Pierangeli, Roma*

17.00 - 17.20 The clinical point of view

*Andrea Lombardi, Milano*

17.20 - 17.30 Discussion





RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Wednesday, June 19

15:00 - 17:30

Aula 6

>>> Pre-Conference advanced course

### Complexities of HIV management: when the going gets tough... the tough get going!

The aim of this pre-congressional course is to reflect on some topics in the management of HIV infection of high clinical complexity. The simultaneous presence of multiple comorbidities can create extreme difficulties for clinicians in the daily clinical management of the person living with HIV. The course is aimed at young infectivologists who will be able to interactively discuss with tutors the approach of five different HIV-related issues. The course aims to critically analyse diagnostic and therapeutic choices in order to synthesise practical management principles useful in clinical practice.

**Chairs: Teresa Bini (Milano), Carmela Pinnetti (Roma)**

**15.00 - 15.20 Saturday Naive Fever: when two (or more) infections are better than one**

*Annalisa Mondì, Roma*

Background:

This case study analyses the simultaneous presence of multiple opportunistic infections during a recent HIV diagnosis. This case report will allow a discussion of the main diagnostic tests, differential diagnosis and timing of initiation of the different therapies.

**15.20 - 15.30 Discussion**

**15.30 - 15.50 Atypical mycobacteriosis yes or not: that is the question**

*Andrea Giacomelli, Milano*

Background:

This case report is about a male patient who has been diagnosed with late HIV infection, visceral KS and IRIS-atypical mycobacteriosis. The patient presented with fever and lymphadenopathy after cART introduction; an initial worsening of symptoms with abdominal pain needed a surgical operation and several modifications of antimycobacterial therapy. The clinical presentation of IRIS and mycobacteriosis, as well as the difficulties in the diagnosis and in the choice of the correct antimycobacterial treatment, are discussed.

**15.50 - 16.00 Discussion**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**16.00 - 16.20 End-stage liver disease in HIV: when and how to get ready for transplant?**

*Marco Merli, Milano*

Background:

Liver transplant in PWH increased significantly in the last 20 years, thanks to the improvements in antiretroviral treatment and prolonged survival. The coinfection with HDV, the alcohol-related liver disease and the increasing prevalence of non-alcoholic fatty liver disease are the current major determinants of end-stage liver disease. HBV/HDV coinfection may have a more aggressive and often unpredictable course in PWH, making liver transplantation the only curative strategy, with success rates related to both transplant timing and patients overall condition (both clinical and social) at the time of transplantation. This clinical case is about a HBV/HDV coinfecting PWH who underwent liver transplant and describes the complications that an ID physician has to manage when caring a PWH undergoing liver transplant.

**16.20 - 16.30 Discussion**

**16.30 - 16.50 Empathetic Care in Action: Navigating the Complex Journey of Transgender Individuals Living with HIV**

*Giuseppe Lapadula, Monza MB*

Background:

The analysis of this clinical case aims to review the clinical management of a transgender PWH. The main screening tests for infectious and oncological pathologies, the choice of antiretroviral therapy and the social issues of retention in care will be discussed.

**16.50 - 17.00 Discussion**

**17.00 - 17.20 What ulcer can I do for you?**

*Nicolò Girometti, London UK*

Background:

This clinical case is about a male patient that presented at HIV/GUM outpatient clinic for genital warts; the physical examination instead showed several genital ulcerations and unilateral vision loss. The patient has been diagnosed with syphilis some years before, but he hadn't be advised to start PrEP. HIV rapid test was positive and later malignant syphilis with optic neuritis was diagnosed. Differential diagnoses of genital ulcers are illustrated and the need of STI testing and PrEP in preventing HIV infection is discussed.

**17.20 - 17.30 Discussion**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Wednesday, June 19

**15:00 - 17:30**

**Aula 7**


>>> Pre-Conference advanced course

### Ageing in people with HIV: a feasible challenge

Ageing is a physiologic process consisting of physical and mental changes. It is primarily influenced by a genetic factors but also by various external factors including diet, exercise, stress, and smoking. HIV infection has been associated with early ageing. Frailty is a clinically state increased vulnerability, resulting from age-associated declines in physiologic reserve and function across multiple organ systems, such that the ability to cope with everyday or acute stressors is compromised. Frailty is strictly associated with ageing and quality of life. Peoples living with HIV (PWH) are at increased risk of myocardial infarction: a recent trial has confirmed a beneficial impact of statin therapy also in PWH older than 40 yo with a low cardiovascular risk. Other comorbidities such as diabetes, hypertension and depression contribute to polypharmacy in PWH. The aim of the course is to analyze the principle issues regarding Ageing in PWH and how to manage them focusing on practical recommendations.

**Chairs: Giusi Giupponi (Como), Filippo Leserri (Roma), Nicola Squillace (Monza)**

<b>15.00 - 15.30</b>	<b>Results of a Survey about Quality of Life in persons with HIV</b>	<i>Nicoletta Policek, Edinburgh UK</i>
<b>15.30 - 16.00</b>	<b>What is frailty and how can we prevent and manage it?</b>	<i>Jovana Milic, Modena</i>
<b>16.00 - 16.10</b>	<b>Discussion</b>	
<b>16.10 - 16.40</b>	<b>Less is more: how can we manage polypharmacy in persons with HIV?</b>	<i>Micol Ferrara, Torino</i>
<b>16.40 - 17.10</b>	<b>If I feel sad, what should I do? Depression burden in persons with HIV</b>	<i>Maria Grazia Strepparava, Milano</i>
<b>17.10 - 17.30</b>	<b>Discussion</b>	



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Wednesday, June 19

**14:00 - 15:00**
**Sala Germania**

&gt;&gt;&gt; Parallel Session

### Donne - Studio Woddol

**Chair: Antonella Cingolani (Milano)**
**15:00 - 17:30**
**Aula Lazzati**

&gt;&gt;&gt; Special Session

### RaccontART Contest Awards: incontro con le scuole finaliste e premiazione

Giunto alla decima edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmesse e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.

**Chairs: Anna Caraglia (Roma), Francesca Ceccherini Silberstein (Roma), Margherita Errico (Milano)**
**15.00 - 15.15 Benvenuto dei Presidenti ICAR 2024**

*Antonella Cingolani, Roma  
Antonio Di Biagio, Genova  
Massimo Farinella, Roma  
Giulia Carla Marchetti, Milano*

**15.15 - 15.30 Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica**
**15.30 - 17.00 Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**
**17.00 - 17.15 Premiazione primi 3 classificati**

*Adriano Lazzarin, Milano*

**17.15 - 17.30 Conclusioni**



**Presidenza del Congresso**  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**18:00 - 19:00**

**Auditorium**

>>> Symposium

*With an unrestricted educational grant from Gilead Sciences*

## How to meet patient needs in PWH?

The current HIV care paradigm goes beyond the concept of suppression of plasma HIV-RNA viral load and recovery of CD4+T cells by also taking into consideration all those factors, pharmacological and non pharmacological, general or tailored to the individual, that make long-term success of antiretroviral therapy (ART) possible. In this context, a person-centered approach must meet the needs and expectations of people with HIV (PWH) in order to ensure their long-term therapeutic success. The symposium aims to provide new knowledge about HIV and hepatitis viruses, especially in the most difficult-to-treat populations, such as PWH with suboptimal adherence and PWH with HBV/HDV coinfection. Through an interactive talk, experts will discuss current and future challenges and innovative strategies that can address the unmet needs of PWH, including those with HBV/HDV coinfection, by supporting individuals to overcome clinical issues and improve outcomes and quality of life.

**Chairs: Giulia Carla Marchetti (Milano), Cristina Mussini (Modena)**

18.00 - 18.15	<b>Optimizing antiretroviral treatment in PWH with a person-centered approach</b>	<i>Andrea Antinori, Roma</i>
18.15 - 18.30	<b>The importance of forgiveness for the sustained HIV virologic suppression</b>	<i>Franco Maggiolo, Fabro TR</i>
18.30 - 18.45	<b>Improving outcomes of HBV/HDV infection among PWH</b>	<i>Massimo Puoti, Milano</i>
18.45 - 19.00	<b>Discussion</b>	<i>Andrea Antinori, Roma Franco Maggiolo, Fabro TR Giulia Carla Marchetti, Milano Cristina Mussini, Modena Massimo Puoti, Milano</i>

**19:00 - 20:30**

**Auditorium**

>>> ICAR 2024 Opening Session

**Chairs: Antonella Cingolani (Roma), Antonio Di Biagio (Genova), Massimo Farinella (Roma), Giulia Carla Marchetti (Milano)**

19.00 - 19.15	<b>Introducing ICAR 2024: Chairs' welcome addresses</b>	
19.15 - 19.20	<b>SIMIT President welcome addresses</b>	<i>Roberto Parrella, Napoli</i>
19.20 - 19.40	<b>Authorities' welcome addresses</b>	<i>Rocco Bellantone, Roma Antonio Gasbarrini, Roma</i>
19.40 - 19.50	<b>RaccontART: the three Winners</b>	<i>Adriano Lazzarin, Milano</i>
19.50 - 20.30	<b>Keynote Lectures: The Year of PrEP</b>	

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024

RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT  
Società Italiana di  
Microbiologia e  
Immunologia

www.icar2024.it



### Chair: Andrea Antinori (Roma)

#### 19.50 - 20.10 **Mauro Moroni Memorial Lecture: "Ending HIV through PrEP: Sheena McCormack, London UK the impact of PrEP on the trajectories of new infections"**

Two European PrEP trials confirmed the high biological efficacy of PrEP in 2015, boosting prevention efforts. The French government responded quickly and implemented a national programme through hospital clinics. The UK government stalled, but the sexual health clinic network supported those able to access PrEP through personal purchase of drug online at affordable prices. The Community raised awareness and charities supported those unable to purchase drug themselves. The impact on new infections was clear at clinic level, and now in national surveillance data. Even in the context of 95:95:95 for diagnosed: on treatment: undetectable, PrEP has an impact. However, there is room for improvement as we're still not diagnosing HIV quickly enough, and shifting social norms would really help in this space, particularly with respect to migrant populations.

### Chair: Sandro Mattioli (Bologna)

#### 20.10 - 20.30 **Giulio Maria Corbelli Memorial Lecture: "The era of PrEP: time to end the AIDS crisis?"**

*Daniele Calzavara, Milano*


PrEP represents one of the greatest opportunities among the strategies we currently have to prevent HIV infection. The social and anthropological impacts of PrEP have generated an enhanced understanding of people's sexualities. These are experience with more self-determination and empowerment, creating opportunities for educational interventions, both in personal and collective perspectives. However, this extraordinary tool could be much more powerful. At the moment the application and distribution of PrEP patchy and unevenly distributed within the national prevention system. The result is that its revolutionary power is still underutilized and largely inaccessible.

#### 20.30 - 20.45 **Closing remarks**

*Antonella Cingolani, Roma  
Antonio Di Biagio, Genova  
Massimo Farinella, Roma  
Giulia Carla Marchetti, Milano*

## 20:45 - 22:30

>>> ICAR 2024 Welcome Reception



## Thursday, June 20

**09:00 - 10:00**

**Plenary-Aula Lazzati**

>>> Keynote Lectures

**Chairs: Antonella d'Arminio Monforte (Milano), Carlo Torti (Roma)**

**09.00 - 09.30 Bridging to the future with long-acting therapies**

*Cristina Mussini, Modena*

Recently, the field of anti-HIV therapy has been further revolutionized by the introduction of long-acting ART. The combination of CAB and RPV represents the first approved injectable long-acting ART for PWH. This combination has demonstrated high efficacy and safety in both registration and real-life studies. Despite the well-known advantages of the CAB/RPV injectable regimen, such as convenience, privacy, stigma reduction, and improved medication management, there are still some barriers to its widespread use. The lecture will provide a summary and update on currently available long-acting antiretrovirals, as well as those in development, and will discuss the challenges involved in their effective implementation.

**09.30 - 10.00 Harnessing the microbiome in HIV vaccine responses**

*Roger Paredes, Badalona  
Catalonia ES*

In the setting of HIV infection, specific microbiome signatures have been linked, on the one hand, to disease progression and on the other, to immune-mediated viral control. Given its key role in shaping the host's adaptive immune response and in modulating the inflammation, the microbiome may be exploited to provide new opportunities to pursue an HIV cure.

**10:05 - 11:05**

**Aula Lazzati**

>>> Symposium

### The role of non-biomedical primary prevention in the end HIV strategies

Information, education and interventions to promote behavior changes have been the cornerstone of HIV prevention for more than two decades. Since 2010 UNAIDS program has called for the inclusion of antiretroviral treatment as a key pillar in the global strategy to control the spread of HIV infection, thus supporting the concept of treatment as prevention. More recently, oral pre-exposure prophylaxis (PrEP) has been demonstrated to be highly efficacious and often effective in public health. In this context non-biomedical interventions for primary prevention, are often seen as having a marginal role in the context of HIV elimination program, although it seem unlikely that biomedical interventions alone will eventually lead to ending the HIV epidemic. In this round table we will discuss the evidence base and the potential impact of several aspects of non-biomedical primary prevention including comprehensive sexuality education, communication for young people through social media and interventions for vulnerable population such as migrants.

**Chairs: Massimo Farinella (Roma), Enrico Girardi (Roma)**

Round table

**10.05 - 10.15 Sexuality education: the EduforIST project**

*Lara Tavoschi, Pisa*



**10.15 - 10.25 Social effectiveness and communication among young people** *Antonella Camposeragna, Roma*

**10.25 - 10.35 Migrant populations** *Tullio Salvatore Prestileo, Palermo*

**10.35 - 10.45 Transgender populations** *Antonia Monopoli, Milano*

**10.45 - 11.05 Discussion**

**10:05 - 11:05**

***Aula Bausola***

>>> Symposium

## **Back to the future of COVID-19: virus evolution, host susceptibility and clinical peculiarities**

The SARS-CoV-2 epidemic has been changing over time, and COVID-19 is transforming from a pandemic to an endemic disease. A great number of genotypic sequences have demonstrated the evolutionary distance of SARS-CoV-2 from 2019 to date. A deep insight into the mechanisms of viral evolution, from the natural selection of advantageous variants to the emergence of drug resistance, will be useful to understand changes in transmissibility, disease severity and immune escape. To date, COVID-19 burden has disproportionately affected the immunocompromised individuals. Therefore, the knowledge of immunogenicity elicited by natural infection and vaccines among them might be relevant for effective management, in terms of booster vaccination, pre-exposure prophylaxis, early access to treatment, and appropriate inpatients care. Post Acute Sequelae of COVID-19 (PASC) represent a mental health challenge, with neuropsychiatric problems that display a novel model of post-viral brain involvement. COVID-19 is associated with the release of pro-inflammatory cytokines that can induce various biological dysregulations, including brain tissue injury. Neuroinflammation may additionally accelerate the progression of various neurodegenerative and neuropsychiatric complications. The goal of the last section of the meeting is to update and discuss mechanisms of long-term mental health issues in people with PASC.

**Chairs: Giordano Madeddu (Sassari), Alessandra Vergori (Roma)**

**10.05 - 10.20 Key drivers of SARS-CoV-2 evolutionary direction: from natural selection to drug-resistance** *Maurizio Zazzi, Siena*

**10.20 - 10.25 Discussion**

**10.25 - 10.40 COVID-19 tie break: a hard shift for immunocompromised patients** *Chiara Agrati, Roma*

**10.40 - 10.45 Discussion**

**10.45 - 11.00 Pathways and markers of virus and immune-related CNS injury in long-COVID** *Simone Beretta, Monza*

**11.00 - 11.05 Discussion**



19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

20  
24



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**10:05 - 11:05**

**Aula 5**

>>> Expert Meeting

*With an unrestricted educational grant from MSD Italy*

### **Winning cardiometabolic comorbidities in HIV: the best place for doravirine**

This session aims to contribute to understanding the positioning of doravirine in clinical practice and the possibility of including this NNRTI in ART regimens to improve long-term follow-up. In particular, two randomized trials, DRIVE-FORWARD and DRIVE-AHEAD, suggest that doravirine is a viable option for ART, with a particular benefit to the metabolic health of people with HIV due to its excellent metabolic profile, particularly with respect to lipids and body weight. Metabolic health refers to a clinical construct that considers the net advantage for the patient regarding multiple metabolic parameters captured by body composition data (including BMI and visceral and liver fat accumulation), lipid fractions, glucose and insulin resistance, kidney function, and bone turnover. Moreover, metabolic health is not just the absence of metabolic diseases but rather a road map for healthy living. The pathway to improve metabolic health includes lifestyle interventions and a proactive antiretroviral approach to be considered in a patient-centred intervention.

**Chair: Cristina Mussini (Modena)**

**Discussants: Antonella Castagna (Milano), Simona Di Giambenedetto (Roma), Roberta Gagliardini (Roma), Cristina Gervasoni (Milano)**

**10:05 - 11:05**

**Aula 7**

>>> Themed Discussion

### **People living with HIV: thinking of QoL**

**Chairs: Roberto Gulminetti (Pavia), Vincenzo Spagnuolo (Milano)**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**10.05 - 10.08 Introduction***Roberto Gulminetti, Pavia  
Vincenzo Spagnuolo, Milano*

**10.08 - 10.15 Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study**  
ID 447 TD 1

*Claudia Bartalucci, Genova*

**10.15 - 10.22 Patient-reported outcomes (PROs) in people living with HIV treated with long-acting injectable antiretroviral therapy (LAI-ART)**  
ID 384 TD 2

*Stefania Arsuffi, Brescia*

**10.22 - 10.29 Enhancing adherence and treatment satisfaction in people living with HIV: the impact of cabotegravir plus rilpivirine long-acting in real life**  
ID 366 TD 3

*Riccardo Schiavoni, Genova*

**10.29 - 10.36 Clinical experience with Doravirine: real-life study of therapeutic efficacy and influence on metabolic profile of dual versus triple antiretroviral regimens in a tertiary hospital of Milan**  
ID 260 TD 4

*Riccardo Nardo, Milano*

**10.36 - 10.43 Rapid ART initiation and Retention in care of people living with HIV: a six-years observational study in foreigners versus Italian-borne**  
ID 258 TD 5

*Lidia Gazzola, Milano***10.43 - 11.05 Discussion****11:10 - 12:10****Aula Lazzati**

## &gt;&gt;&gt; Symposium

*Sponsored by ViiV Healthcare***Are three-drug ARV regimens still needed for long-term treatment success?**

In recent decades, the needs of people living with HIV have evolved as life expectancy has greatly increased. Current ARV regimens are required to meet the ambitious goal of long-term treatment success: to do so, they must guarantee high genetic barrier to resistance, long-term efficacy, optimal long-term safety and tolerability, simplicity and ensure good quality of life. Over the last years, we have witnessed the latest evolution of ART, with the development of two drug regimens capable of ensuring high rates of treatment success, at similar levels to three drug regimens, but with less ARV agents. The aim of this round table is to critically discuss the role of DTG/3TC as a two-drug regimen capable of ensuring long term treatment success.

**Chairs: Roberto Gulminetti (Pavia), Cristina Mussini (Modena)****11.10 - 11.15 Opening and introduction***Roberto Gulminetti, Pavia  
Cristina Mussini, Modena***Round table**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**11.15 - 11.25 Potency and barrier to resistance of DTG/3TC** *Diego Ripamonti, Bergamo*

**11.25 - 11.35 Sustained virologic efficacy over time with DTG/3TC** *Simona Di Giambenedetto, Roma*

**11.35 - 11.45 Long term tolerability of DTG/3TC** *Gabriella d'Ettorre, Roma*

**11.45 - 11.55 Quality of life and people satisfaction with DTG/3TC** *Alessandra Vergori, Roma*

**11.55 - 12.10 Discussion and take-home messages**

*Moderators:  
Roberto Gulminetti, Pavia  
Cristina Mussini, Modena*

*Discussants:  
Gabriella d'Ettorre, Roma  
Simona Di Giambenedetto,  
Roma  
Diego Ripamonti, Bergamo  
Alessandra Vergori, Roma*

**11:10 - 12:10**

**Aula Bausola**

>>> Symposium

*With an unrestricted educational grant from Gilead Sciences*

### **Infectious disease management in patients living with onco-hematological malignances: focus on COVID-19 and invasive fungal infections (IFI)**

The session aims to reflect on the urgency of improving the management of fungal infections and Covid-19 in hematology patients who face unique challenges related to compromised immune system resulting from chemotherapy treatments, malignant hemopathy, and HSCT. In this context, the onset of invasive fungal infections represents a significant threat, bringing with it the risk of serious complications and even mortality in an already vulnerable population. The global emergency of Covid-19 has further complicated the situation for hematology patients, making it crucial to deep into the relationships between immunocompromise and viral infection and potential complications resulting from drug-drug interactions (DDIs). Managing these dual threats requires in-depth understanding, targeted treatment plans, and appropriate clinical care. There is a need to define best practices in the diagnosis and treatment of invasive fungal infections, as well as the unique challenges in managing SARS-CoV-2 infection in hematological patients. Multidisciplinary collaboration between different professional figures is an essential element to guarantee complete assistance aimed at preventing complications and containing drug resistance, especially with regards to fungal infections.

**Chair: Pierluigi Viale (Bologna)**

**11.10 - 11.20 Clinical features and management: a multidisciplinary approach** *Pierluigi Viale, Bologna*

**11.20 - 11.40 Clinical debate on COVID-19** *Michele Bartoletti, Rozzano MI  
Giusy Tiseo, Pisa*

**11.40 - 12.00 Clinical debate on invasive fungal infections (IFI)** *Michele Bartoletti, Rozzano MI  
Giusy Tiseo, Pisa*



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

12.00 - 12.10 Practical considerations

Pierluigi Viale, Bologna

**11:10 - 12:10**

**Aula 5**

>>> Oral Communications

## HIV epidemiology and testing promotion

**Chairs: Anna Maria Geretti (Roma), Ilenia Pennini (Padova)**

11.10 - 11.15 Introduction

Anna Maria Geretti, Roma  
Ilenia Pennini, Padova

11.15 - 11.25 **Measuring HIV knowledge and attitudes in the healthcare setting: Italian results from an ECDC/EACS survey**

ID 210 OC 1

Maria Mazzitelli, Padova

11.25 - 11.35 **Modena and Emilia Romagna HIV Surveillance: the application of ECDC HIV Modelling Tool**

ID 353 OC 2

Marianna Menozzi, Modena

11.35 - 11.39 Discussion

11.39 - 11.49 **HIV testing in Italian community and outreach sites: COBATEST network, 2020-2023**

ID 149 OC 3

Paolo Meli, Chiuduno BG

11.49 - 11.59 **Estimating the potential health economic value of universal opt-out HIV testing in emergency departments in Italy: A modelling study**


ID 83 OC 4

Antonella d'Arminio Monforte,  
Milano

11.59 - 12.03 Discussion

12.03 - 12.10 Conclusion

Anna Maria Geretti, Roma  
Ilenia Pennini, Padova



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**11:10 - 12:10****Aula 6**

&gt;&gt;&gt; Oral Communications

**Immune responses to vaccination and emerging infections****Chairs: Mara Biasin (Milano), Andrea Cossarizza (Modena)****11.10 - 11.15 Introduction***Mara Biasin, Milano  
Andrea Cossarizza, Modena***11.15 - 11.25 Humoral and cellular immune response after one year from  
ID 246 OC 5 Mpox virus infection***Eleonora Cimini, Roma***11.27 - 11.37 Anti-MPXV humoral and cellular immune response one year  
ID 223 OC 6 after mpox infection or MVA-BN vaccination***Giulia Matusali, Roma***11.39 - 11.49 SARS-CoV-2 spike protein and plasma from COVID-19 patients  
ID 109 OC 7 induce extracellular traps by myeloid-derived suppressor cells***Germana Grassi, Roma***11.51 - 12.01 Antiretroviral therapy restores naïve T cell frequencies and  
ID 134 OC 8 functionality in PLWH***Beatrice Dallan, Ferrara***12.03 - 12.10 Conclusion***Mara Biasin, Milano  
Andrea Cossarizza, Modena***12:15 - 13:15****Aula Lazzati**

&gt;&gt;&gt; Symposium

**Three elephants in the room: clinical approach to the most relevant comorbidities related to HIV infection**

Although highly effective and well-tolerated therapies are now available, people with HIV continue to be at increased risk of developing certain comorbidities. In particular cardiovascular diseases, cancers and mental health conditions. The aim of the symposium will be to explore the latest evidence that attempts to explain the underlying causes of this phenomenon.

**Chairs: Paola Cinque (Milano), Nicoletta Frattini (Milano)****12.15 - 12.30 Lipids or inflammation: which is the main driver of  
cardiovascular events in person with HIV?**  
*Giuseppe Vittorio Luigi De Socio, Perugia*

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

12.30 - 12.35 Discussion

12.35 - 12.50 **Mental health at the intersection of social and medical factors** *Alan Winston O' Keefe, London UK*

12.50 - 12.55 Discussion

12.55 - 13.10 **"Did we really break down the walls?" Lymphoproliferative disorders in person with HIV today** *Luisa Verga, Monza*

13.10 - 13.15 Discussion

**12:15 - 13:15**

**Aula Bausola**

>>> Expert Meeting

### COVID-19 risk assessment and prophylaxis in fragile population

COVID-19 remains a significant risk for the immunocompromised for being hospitalized or dying from severe SARS-CoV-2 infection, given their poor responsiveness to vaccination or impaired immunity after natural infection. Therefore, passive immunization through long-acting monoclonal antibodies (mAbs) offers a needed approach by pre-exposure prophylaxis (PrEP), a novel preventive strategy for high-risk populations. This session will present updated data on the anti-SARS-CoV-2 drug sipavibart, a long-acting neutralizing human monoclonal antibody directed against new emerging SARS-CoV-2 variants, which can potentially be used to protect immunosuppressed people from severe disease. Current characterization of risk assessment among immunocompromised persons, new results of sipavibart from randomized clinical and immunobridging trials, and implementation strategy of pre-exposure prophylaxis with monoclonal antibodies in the clinical and public health setting will be the main topics of the session designed to optimize the prevention approach of SARS-CoV-2 in high-risk population.

**Chairs: Alessandra Bandera (Milano), Paolo Bonfanti (Monza)**

12.15 - 12.35 **Risk assessment of immunocompromised people at risk of severe SARS-CoV-2 infection** *Enrico Girardi, Roma*

12.35 - 12.55 **Update on sipavibart in SARS-CoV-2 pre-exposure prophylaxis** *Andrea Antinori, Roma*

12.55 - 13.15 **Round Table: Implementing strategies and access of persons with hematologic conditions to COVID-19 monoclonal antibody prophylaxis** *Discussants:  
Corrado Girmenia, Roma  
Marzia Mensurati, Roma  
Roberto Parrella, Napoli*

**12:15 - 13:15****Aula 5**

&gt;&gt;&gt; Expert Meeting

**PrEP and more**

Numerous efforts have been made to reduce new HIV infections, AIDS cases, and HIV-related deaths in our country. Among various strategies, starting from 2023, Pre-Exposure Prophylaxis for HIV (PrEP) for key populations has become fully reimbursed by the National Health Service (SSN). This has led to a progressive increase in requests for access to the program and the establishment of dedicated clinics throughout the national territory, even in facilities where clinics for Sexually Transmitted Infections and Preventive Strategies were absent or only serving few users. The "PrEPParati" project was therefore conceived to create a training and discussion opportunity among specialists from centers with longer experience to guide, support, and address the challenges and difficulties of these new needs and realities. This session aims to present the highlights and most interesting aspects of what was discussed during the project in order to share this valuable experience with the goal of creating a more uniform and comprehensive implementation within the field of STIs and PrEP.

**Chairs: Giulia Valeria Calvino (Roma), Benedetto Maurizio Celesia (Catania)****12.15 - 12.20 Introduction****12.20 - 12.40 Complex PrEP Clinic: beyond a pill there's an unmet clinical need***Nicolò Girometti, London UK***12.40 - 12.45 Discussion****12.45 - 13.05 Roadmap for implementing PrEP and STIs services in your clinic: the "PrEPParati" Project***Davide Moschese, Milano***13.05 - 13.10 Discussion****13.10 - 13.15 Take-home messages****12:15 - 13:15****Aula 6**

&gt;&gt;&gt; Oral Communications

**Long Acting injectables: the Italian experience****Chairs: Teresa Bini (Milano), Diego Ripamonti (Bergamo)**

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**12.15 - 12.20 Introduction**

*Teresa Bini, Milano  
Diego Ripamonti, Bergamo*

**12.20 - 12.30 One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohLART study**  
ID 205 OC 9

*Camilla Muccini, Milano*

**12.32 - 12.42 Effectiveness of long-acting ART with cabotegravir/rilpivirine in the Icona Cohort**  
ID 185 OC 10

*Roberta Gagliardini, Roma*

**12.44 - 12.54 Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort**  
ID 388 OC 11

*Giada Canavesi, Legnano*

**12.56 - 13.06 Pittsburgh sleep quality index (PSQI) changes in virologically suppressed people living with HIV switching to long acting cabotegravir and rilpivirine**  
ID 179 OC 12

*Angelo Dargenio, Bari*

**13.08 - 13.15 Conclusion**

*Teresa Bini, Milano  
Diego Ripamonti, Bergamo*

**12:15 - 13:15**

**Aula 7**

>>> Short Communications

**Novel insights in the management of chronic viral hepatitis**

**Chairs: Nicola Coppola (Napoli), Valentina Svicher (Roma)**





Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**12.15 - 12.18 Introduction**

*Nicola Coppola, Napoli  
Valentina Svicher, Roma*

**12.18 - 12.25 Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history**

ID 432 SC 1

*Mattia Simion, Modena*

**12.27 - 12.34 Safety and effectiveness of switching PWH with occult HBV infection to tenofovir-sparing regimens**

ID 235 SC 2

*Vincenzo Malagnino, Roma*

**12.36 - 12.43 Occult HBV infection and archived resistance to 3TC could predict virological failure during 3TC/DTG maintenance antiretroviral therapy: a retrospective study**

ID 466 SC 3

*Sara Occhineri, Pisa*

**12.45 - 12.52 Risk of Hepatitis B reactivation in people with HIV (PWH) with isolated anti-core antibody (HBcAb) after switch to 2DR strategies with lamivudine(3TC)/dolutegravir(DTG)**

ID 423 SC 4

*Pierluigi Francesco Salvo, Roma*

**12.54 - 13.01 HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir**

ID 232 SC 5

*Stefano D'Anna, Roma*

**13.03 - 13.10 Heterogeneity in the diagnostic sensitivities of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study**

ID 181 SC 6

*Romina Salpini, Roma*

**13.12 - 13.15 Conclusion**

*Nicola Coppola, Napoli  
Valentina Svicher, Roma*

**13:15 - 14:15**

**Aula Bausola**

>>> Short Communications

**Sexual health and love's labours**

**Chairs: Alessandra Latini (Roma), Bruno Marchini (Lodi)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**13.15 - 13.18 Introduction**

*Alessandra Latini, Roma  
Bruno Marchini, Lodi*

**13.18 - 13.25 A hidden challenge: STIs detection prevalence during nPEP follow up. A retrospective analysis**

ID 359 SC 7

*Nicholas Brian Bana, Milano*

**13.27 - 13.34 Increasing Gonorrhoea and Chlamydia infections observed in MSM in the early 2024**

ID 212 SC 8

*Christof Stingone, Roma*

**13.36 - 13.43 Sexually transmitted infections in men-who-have-sex-with-men with HIV resistant to tenofovir/emtricitabine and/or cabotegravir**

ID 271 SC 9

*Tommaso Clemente, Milano*

**13.45 - 13.52 Applying IANS consensus guidelines for anal cancer screening to men who have sex with men living with HIV: a focus on the HRA referral rate**

ID 124 SC 10

*Maria Gabriella Donà, Roma*

**13.54 - 14.01 Inadequate compliance with STIs vaccinations among individuals attending a sexually transmitted infection clinic**

ID 42 SC 11

*Gabriele Cavazza, Milano*

**14.03 - 14.10 Doxycycline post-exposure prophylaxis (DoxyPEP) real-life effectiveness in a cohort of men who have sex with men in Milan, Italy**

ID 313 SC 12

*Angelo Roberto Raccagni,  
Milano*

**14.12 - 14.15 Conclusion**

*Alessandra Latini, Roma  
Bruno Marchini, Lodi*

**13:15 - 14:15**

**Aula 5**

>>> Short Communications

**PrEParing for the future of prevention**

**Chairs: Miriam Lichtner (Latina), Paolo Meli (Bergamo)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

---

**13.15 - 13.18 Introduction**

*Miriam Lichtner, Latina  
Paolo Meli, Bergamo*

---

**13.18 - 13.25 Impact of PrEP cost on prophylaxis initiation in an Italian centre**

ID 251 SC 13

*Serena Venturrelli, Bergamo*

---

**13.25 - 13.32 5 years activity of the Bergamo Fast Track City network: from 2019 looking toward the future**

ID 182 SC 14

*Ilaria Mercurio, Chiuduno BG*

---

**13.32 - 13.36 Discussion**

---

**13.36 - 13.43 How the perception of PrEP has changed in the PrEP Point Plus (PPP) user group**

ID 5 SC 15

*Sandro Mattioli, Bologna*

---

**13.43 - 13.50 Factors associated with PrEP start after nPEP conclusion. A retrospective analysis**

ID 345 SC 16

*Nicholas Brian Bana, Milano*

---

**13.50 - 13.54 Discussion**

---

**13.54 - 14.01 Interest for long-acting PrEP use in the Italian LGBTQIA+ community: a multicentric survey**

ID 154 SC 17

*Marco Stizioli, Montichiari*

---

**14.01 - 14.08 What about a change? A survey in PrEP users about interest in injectable Long-Acting agents**

ID 394 SC 18

*Alessandra Bianchi, Milano*


---

**14.08 - 14.12 Discussion**

---

**14.12 - 14.15 Conclusion**

*Miriam Lichtner, Latina  
Paolo Meli, Bergamo*



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**13:15 - 14:15****Aula 6**

&gt;&gt;&gt; Themed Discussion

**Antiretroviral therapy: thinking of durability****Chairs: Giordano Madeddu (Sassari), Franco Maggiolo (Fabro TR)****13.15 - 13.18 Introduction***Giordano Madeddu, Sassari  
Franco Maggiolo, Fabro TR***13.18 - 13.25 Durability of doravirine-dolutegravir dual combination in a multicenter cohort of elderly people with HIV**

ID 33 TD 6

*Maria Mazzitelli, Padova***13.25 - 13.32 Comparing the efficacy and safety of dolutegravir+lamivudine vs bicittegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens in a multicenter cohort**

ID 408 TD 7

*Arturo Ciccullo, L'Aquila***13.32 - 13.39 Similar Efficacy, Safety and CD4 T cell increase up to Week 96 observed in Fostemsavir (FTR) based regimens from the BRIGHT-E study and Dolutegravir (DTG) based regimens from the VIKING-3 study in multidrug resistant (MDR) HIV-1**

ID 160 TD 8

*Antonella Castagna, Milano***13.39 - 13.46 Exploring the Use of Darunavir Boosted plus Dolutegravir in Highly Treatment-Experienced HIV Population: A Retrospective Cohort Study**

ID 383 TD 9

*Andrea De Vito, Alghero***13.46 - 13.53 Real-world data on the effectiveness and safety of bicittegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH): 24-month full dataset results of the Italian BICSTaR cohort**

ID 75 TD 10

*Stefano Rusconi, Legnano MI***13.53 - 14.15 Discussion****13:15 - 14:15****Aula 7**

&gt;&gt;&gt; Short Communications

**HIV associated comorbidities: interplaying matters****Chairs: Giovanni Cenderello (Sanremo IM), Chiara Iaria (Palermo)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**13.15 - 13.18 Introduction**

*Giovanni Cenderello, Sanremo IM  
Chiara Iaria, Palermo*

**13.18 - 13.25 Lipids, weight gain and Body Mass Index in ARV experienced PLWH treated with Doravirine-based treatments: a comparison between dual or triple regimens vs Bictegrovir based triple regimen**

ID 27 SC 19

*Addolorata Masiello, Caserta*

**13.27 - 13.34 Dyslipidemia and real-life prescription of statins among People Living With HIV enrolled in Archi Prevaleat cohort**

ID 127 SC 20

*Benedetto Maurizio Celesia,  
Catania*

**13.36 - 13.43 The dangerous liaisons: Correlation between lipid profile, subclinical atherosclerosis, hepatic steatosis and hepatic fibrosis in PLWH**

ID 28 SC 21

*Alessandra Tartaglia, Foggia*

**13.45 - 13.52 A 48-week randomized controlled study of a home-based, app-monitored physical exercise intervention for older people with sarcopenia (Grow Your Muscle - GYM study): Preliminary results on muscle function and body composition at Week-12**

ID 96 SC 22

*Federica Marmondi, Milano*

**13.54 - 14.01 Changes in bone mineral density in antiretroviral therapy-naive people living with HIV-1 aged over 50 years and starting bictegrovir/emtricitabine/tenofovir alafenamide**

ID 9 SC 23

*Maddalena Giglia, Bologna*

**14.03 - 14.10 Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination?**

ID 354 SC 24

*Alessandra Bailoni, Siena*

**14.12 - 14.15 Conclusion**

*Giovanni Cenderello, Sanremo IM  
Chiara Iaria, Palermo*

**14:20 - 15:20**

**Aula Lazzati**

>>> Symposium

*With an unrestricted educational grant from Gilead Sciences*

**Real-world experiences with TAF-based regimens**

TAF stands as a pivotal advancement in the management of HIV. Its introduction marks a significant milestone for achieving long-term treatment success in PWH. The symposium aims to present and discuss RWE of TAF-based regimens in HIV management across diverse patient populations and healthcare settings. By informing evidence-based decision-making, the symposium seeks to optimize patient care, leading to improved treatment strategies and outcomes for PWH.

**Chair: Simona Di Giambenedetto (Roma)**

**Discussants: Roberta Gagliardini (Roma), Andrea Giacomelli (Milano)**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

14.20 - 14.30 PWH: present and future clinical scenario

Simona Di Giambenedetto,  
Roma*Clinical experiences in real-life settings*14.30 - 14.40 Efficacy of switching to bictegravir/emtricitabine/tenofovir  
ID 166 OC 13 alafenamide in people living with HIV with pre-existing NRTI  
resistances: a real-life experience

Laura Mezzogori, Genova

14.40 - 14.50 Adherence of single tablet antiretroviral regimens in the  
ID 228 OC 14 clinical setting: forgiveness does matter

Viviana Maccario, Torino

14.50 - 15.00 Changes in Body mass index and lipid profile in PWH switching  
ID 141 OC 15 to a regimen without TAF vs PWH continuing TAF. Data from a  
real-life setting

Nicola Squillace, Monza

15.00 - 15.06 Discussion

Roberta Gagliardini, Roma  
Andrea Giacomelli, Milano

15.06 - 15.20 Final considerations

Simona Di Giambenedetto,  
Roma**14:20 - 15:20****Aula Bausola**

&gt;&gt;&gt; Symposium

With an unrestricted educational grant from Pfizer

**Antiviral treatment of COVID-19 for fragile people in the current era**

After the third year of the COVID-19 pandemic, most of the severe COVID-19 burden falls upon immunocompromised patients who cannot mount an endogenous immune response after both vaccination and/or natural infection. SARS-CoV-2 tends to establish persistent infections in patients who are immunocompromised (IC), where disease recovery and viral clearance are needed to initiate further lines of immunosuppressive treatments for the underlying disorder. Since ritonavir-boosted nirmatrelvir is a recognized highly effective oral antiviral therapy for COVID-19, with a large supporting evidence, it should be strongly considered for patients who are immunocompromised if there are no potential drug-drug interactions or if the potential interactions can be safely managed. This session will review more recent data from scientific research and the evidences in the real-world setting.


**Chairs: Andrea Antinori (Roma), Annamaria Cattelan (Padova)**

14.20 - 14.25 Introduction

Andrea Antinori, Roma  
Annamaria Cattelan, Padova14.25 - 14.45 From high-risk patients to persistent infection: focus on  
COVID-19 in the immunocompromised persons

Marco Falcone, Pisa

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



16° CONGRESSO NAZIONALE



Promosso da  
SIMIT  
Società Italiana di Microbiologia  
Immunologia e Infettivologia

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

14.45 - 14.50 Discussion

14.50 - 15.10 Antiviral treatment of COVID-19: insights from controlled trials and real-world evidence

Valentina Mazzotta, Roma

15.10 - 15.15 Discussion

15.15 - 15.20 Take-home messages

Andrea Antinori, Roma  
Annamaria Cattelan, Padova

**14:20 - 15:20**

**Aula 5**

>>> Oral Communications

**Virology and pharmacology across the spectrum of HIV treatment**

**Chairs: Guido Antonelli (Roma), Andrea Calcagno (Torino)**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**14.20 - 14.25 Introduction**Guido Antonelli, Roma  
Andrea Calcagno, Torino

**14.25 - 14.35 Do low-frequency drug-resistant HIV-1 variants have a role on first-line INSTI-containing regimens? A case-control study from the ICONA cohort**

ID 192 OC 16

Maria Santoro, Roma

**14.35 - 14.45 Long Acting Cabotegravir and Rilpivirine plasma and intracellular pharmacokinetics in the Clinical Setting**

ID 54 OC 17

Micol Ferrara, Torino

**14.45 - 14.49 Discussion**

**14.49 - 14.59 Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry**

ID 177 OC 18

Sara Diotallevi, Milano

**14.59 - 15.09 The in vitro genetic barrier to resistance of lenacapavir is not affected by viral subtype or heavy treatment exposure**

ID 368 OC 19

Chiara Paletti, Siena

**15.09 - 15.13 Discussion****15.13 - 15.20 Conclusion**Guido Antonelli, Roma  
Andrea Calcagno, Torino**14:20 - 15:20****Aula 6****>>> Expert Meeting**

With an unrestricted educational grant from Angelini Pharma

### Optimizing the management of patients with skin and soft tissue infections (ABSSSI): focus on fragile population

Acute bacterial skin and skin structure infections (ABSSSI) represent a significant burden on the healthcare system, with increasing incidence and severity, particularly in fragile population, such as the elderly, multi-treated, drug addicts, or people with neuropsychiatric problems. The involvement of resistant organisms, particularly methicillin-resistant *Staphylococcus aureus*, presents additional challenges in the management of these patients, as well as the need of a multidisciplinary approach. The long-acting lipoglycopeptide dalbavancin with activity against Gram-positive organisms, including MRSA, may offer the opportunity for earlier hospital discharge and be considered in the outpatient setting, including home health care, outpatient infusion clinics, or in the emergency department to avoid delay in treatment and prevent inpatient hospital admissions, which represents a relevant issue particularly in patients at high risk of complications.

**Chairs: Antonio Cascio (Palermo), Sergio Lo Caputo (Foggia)**





**Presidenza del Congresso**  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

<b>14.20 - 14.30</b>	<b>Introduction: Gram+ infections, the importance of a specialistic network</b>	<i>Antonio Cascio, Palermo Sergio Lo Caputo, Foggia</i>
<b>14.30 - 14.50</b>	<b>Effectiveness of long-acting antibiotic therapy: clinical and real-life evidences</b>	<i>Ivan Gentile, Napoli</i>
<b>14.50 - 15.10</b>	<b>The long-acting diagnostic-therapeutic path of patients with Gram+ infections: indications for clinical practice</b>	<i>Sergio Carbonara, Bisceglie BT</i>
<b>15.10 - 15.20</b>	<b>Take-home messages</b>	<i>Antonio Cascio, Palermo Sergio Lo Caputo, Foggia</i>

## 15:25 - 16:25

**Aula Lazzati**

### >>> Symposium

#### **Clinical HIV: looking ahead**

The current clinical landscape of HIV encompasses several noteworthy areas of interest. These include managing opportunistic infections, which continue to occur due to a significant number of individuals experiencing AIDS-defining illnesses as well as addressing new challenges related to expanding access to transplantation for selected HIV patients. Despite advances in antiretroviral therapy, surgical techniques, and post-operative care, concerns remain regarding organ rejection, opportunistic infections, and drug interactions. The symposium will focus on gaining new insights into opportunistic infections like tuberculosis and cryptococcosis, and making advances in organ transplantation for person living with HIV. Careful patient selection, close monitoring, and tailored immunosuppressive therapy will be given particular attention.

**Chairs: Cristina Gervasoni (Milano), Sergio Lo Caputo (Foggia)**

<b>15.25 - 15.40</b>	<b>What is still to be done in solid organ transplantation for person living with HIV</b>	<i>Giovanni Guaraldi, Modena</i>
<b>15.40 - 15.45</b>	<b>Discussion</b>	
<b>15.45 - 16.00</b>	<b>Can person living with HIV benefit from short strategies for preventing and treating tuberculosis?</b>	<i>Giovanni Di Perri, Torino</i>
<b>16.00 - 16.05</b>	<b>Discussion</b>	
<b>16.05 - 16.20</b>	<b>Can person living with HIV benefit from short therapy in cryptococcal meningitis?</b>	<i>Spinello Antinori, Milano</i>
<b>16.20 - 16.25</b>	<b>Discussion</b>	

**15:25 - 17:30****Aula Bausola**

&gt;&gt;&gt; Symposium

**Covid-19 and post-Covid conditions in 2024: data from the EuCARE project**

SARS-CoV-2 and its continuous evolution still pose scientific questions and challenges, including those related to its immune pathogenesis and to long-COVID. The pandemic also highlighted the need for research on areas like vaccine hesitancy and non pharmacological interventions, e.g. in school. Thanks to a large international collaboration, the EuCARE project is trying to provide advances in a wide variety of SARS-CoV-2 variants related topics.

**Chairs: Francesca Ceccherini Silberstein (Roma), Maurizio Zazzi (Siena)**

**15.25 - 15.40 International collaboration for pandemic preparedness: the EuCARE Project** *Francesca Incardona, Roma*

**15.40 - 15.45 Neutralizing antibody response to the latest SARS-CoV-2 lineages (WP2)** *Maurizio Zazzi, Siena*

**15.45 - 16.00 Discussion**

**16.00 - 16.10 Interplay between gut-barrier dysfunction, microbial translocation, microbioma and SARS-CoV-2 RNAemia in acutely ill unvaccinated COVID-19 individuals developing long-covid** *Roberta Rovito, Milano*  
ID 292 OC 20


**16.12 - 16.24 Trajectories of the Post COVID-19 condition** *Andrea Santoro, Milano*  
ID 225 OC 21

**16.26 - 16.41 In-hospital mortality study results (WP3 > Hospitalised)** *Alessandro Cozzi-Lepri, London UK*

**16.41 - 16.56 Characterisation of vaccine hesitancy in health care workers (WP3 > HCW)** *Francis Drobniowski, London UK*

**16.56 - 17.11 Exploring mental health of students in association with SARS-CoV-2 preventive measures (WP4)** *Sara Gandini, Milano*

**17.11 - 17.30 Discussion**

**15:25 - 16:25****Aula 5**

&gt;&gt;&gt; Expert Meeting

*With an unrestricted educational grant from Gilead Sciences*

### Tailoring of antiretroviral therapy in PWH who go through therapeutic failure. Experts panel discussion on real clinical scenarios

While modern antiretroviral therapy has been progressing towards increased potency, convenience and durability, controversies in HIV virology and pharmacology remain. This expert meeting focuses on four specific clinical issues: how to manage PWH with drug resistance, low-level viremia, PWH who discontinued long-acting therapies, and PWH with comorbidities and polypharmacy. The goal of this expert meeting is to discuss open controversies in HIV, through an experts panel, to identify timely, appropriate, and individualized treatment approach for these complex clinical scenarios.

**Chairs: Antonella Cingolani (Roma), Antonio Di Biagio (Genova)**

15.25 - 15.30	<b>PWH with resistance associated mutations</b>	<i>Stefano Rusconi, Legnano MI</i>
15.30 - 15.40	<b>Discussion</b>	<i>Antonella Cingolani, Roma Antonio Di Biagio, Genova Stefano Rusconi, Legnano MI</i>
15.40 - 15.45	<b>PWH with low-level viremia</b>	<i>Loredana Sarmati, Roma</i>
15.45 - 15.55	<b>Discussion</b>	<i>Antonella Cingolani, Roma Antonio Di Biagio, Genova Loredana Sarmati, Roma</i>
15.55 - 16.00	<b>Discontinuations after switching to long-acting therapy</b>	<i>Silvia Nozza, Milano</i>
16.00 - 16.10	<b>Discussion</b>	<i>Antonella Cingolani, Roma Antonio Di Biagio, Genova Silvia Nozza, Milano</i>
16.10 - 16.15	<b>PWH with comorbidities and polypharmacy</b>	<i>Stefano Bonora, Torino</i>
16.15 - 16.25	<b>Discussion</b>	<i>Stefano Bonora, Torino Antonella Cingolani, Roma Antonio Di Biagio, Genova</i>

**15:25 - 16:25****Aula 6**

&gt;&gt;&gt; Oral Communications

### Modern challenges in sexual health

**Chairs: Mario Cascio (Milano), Paola Cinque (Milano)**

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**15.25 - 15.30 Introduction**

*Mario Cascio, Milano  
Paola Cinque, Milano*

**15.30 - 15.40 Female sexual dysfunction: prevalence and risk factors in a cohort of women living with HIV**

ID 439 OC 22

*Martina Salvi, Brescia*

**15.42 - 15.52 Knowledge, use and misuse of self-prescribed doxyPEP in a community-based PrEP service**

ID 34 OC 23

*Enrico Caruso, Milano*

**15.54 - 16.04 Effectiveness of MenB vaccination against gonorrhoeae among PrEP users and PWH**

ID 274 OC 24

*Laura Labate, Genova*

**16.06 - 16.16 HPV test in anal specimens: a preliminary evaluation on sampling quality**

ID 446 OC 25

*Alberto Rizzo, Milano*

**16.18 - 16.25 Conclusion**

*Mario Cascio, Milano  
Paola Cinque, Milano*

**15:25 - 16:25**

**Aula 7**

>>> Short Communications

**Factors affecting treatment success: from pharmacology to drug resistance**

**Chairs: Annapaola Callegaro (Milano), Emanuele Focà (Brescia)**

**15.25 - 15.28 Introduction**

*Annapaola Callegaro, Milano  
Emanuele Focà, Brescia*

**15.28 - 15.35 The impact of pharmacogenetics on long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting**

ID 355 SC 25

*Jessica Cusato, Torino*

**15.35 - 15.42 The case of dolutegravir plus darunavir antiretroviral regimens: Is it always useful to double the drug doses?**

ID 25 SC 26

*Dario Cattaneo, Milano*

**15.42 - 15.46 Discussion****15.46 - 15.53 Comparative analysis of islatravir and tenofovir in vitro activity in NRTI resistant HIV-1 harboring the M184V/I mutation**

ID 167 SC 27

*Niccolò Bartolini, Siena*

**15.53 - 16.00 Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy according to subtype over the period 2017-2023**

ID 218 SC 28

*Francesco Bassani, Legnano*

**16.00 - 16.07 Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed people with HIV-1 switching to modern antiretroviral regimens**

ID 322 SC 29

*Elio Gentilini Cacciola, Roma*


**16.07 - 16.14 Ultra-deep sequencing of near full-length HIV-1 genomes for detecting natural resistance to lenacapavir and fostemsavir**

ID 63 SC 30

*Elisabetta Lazzari, Roma*

**16.14 - 16.22 Discussion****16.22 - 16.25 Conclusion**

*Annapaola Callegaro, Milano  
Emanuele Focà, Brescia*

**15:25 - 17:25****Sala Germania**

&gt;&gt;&gt; Special Session

*With an unrestricted educational grant from ViiV Healthcare***Approaching Chemsex user: a multidisciplinary practice**

Chemsex refers to the use of one or more drugs by MSM before or during sexual activity with one or more partners, organized through geolocation meeting apps and involving specific social interaction dynamics. It's a phenomenon known within the MSM community for many years, but recently, the need for competent support for problematic Chemsex use, which increased during the pandemic, has emerged. However, support is currently scarce. The market is constantly producing new, cheaper substances with unclear effects, posing unpredictable risks. Users may struggle to recognize their problematic use, partly due to stigma and due to its difference from the stereotype of more common and studied substance use, like opioids or cocaine, making it harder to seek help before the situation becomes severe or irreversible. Chemsex can facilitate the spread of STIs, including HIV, due to lowered inhibitions. While many engage in Chemsex without severe consequences, for others, it can develop into a dangerous addiction that's hard to overcome. Some substances can lead to potentially irreversible psychotic crises. There's an urgent need for training among infectious disease, psychiatry, psychology, emergency department professionals, pharmacologists, and addiction service workers, involving users, volunteers and professional operators.

**Chairs: Massimo Cernuschi (Milano), Giorgia Fracca (Milano)****Discussants: Massimo Cernuschi (Milano), Donatello Zagato (Milano)**

15.25 - 15.35	<b>Welcome and introduction</b>	<i>Massimo Giuseppe Luigi Cernuschi, Milano Giorgia Fracca, Milano</i>
15.35 - 15.55	<b>PrEP and chemsex, description of the phenomenon in the Milan check point cohort</b>	<i>Enrico Caruso, Milano</i>
15.55 - 16.15	<b>NPS (Novel Psychoactive Substances) epidemiological overview and toxicological monitoring</b>	<i>Marta Ciambella, Roma</i>
16.15 - 16.35	<b>MDPV (methylenedioxypropylvalerone): a survey on awareness and knowledge among users of a Milanese PrEP service</b>	<i>Alessandra Maria Bianchi, Milano</i>
16.35 - 16.55	<b>Chemsex and possible implications on antiretroviral therapy</b>	<i>Davide Moschese, Milano</i>
16.55 - 17.15	<b>Round Table: Build shared knowledge between users, volunteers, social and health workers</b>	<i>Moderator: Massimo Giuseppe Luigi Cernuschi, Milano</i>  <i>Discussants: Daniele Calzavara, Milano Enrico Caruso, Milano Massimo Giuseppe Luigi Cernuschi, Milano Marta Ciambella, Roma Giorgia Fracca, Milano Filippo Leserri, Roma Davide Moschese, Milano</i>

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

17.15 - 17.25 Closing remarks

Massimo Giuseppe Luigi  
Cernuschi, Milano  
Giorgia Fracca, Milano

**16:30 - 17:30**

**Aula Lazzati**

>>> Symposium

### The future of STI prevention and care: one size does not fit all

Join our symposium on STI prevention and care. Against a backdrop of evolving landscapes in healthcare and policy, we will probe into emerging aspects of STI surveillance, placing Italy within the European context. Hosted by the Journal Sexually Transmitted Infections, a discourse on standards will navigate the complexities of delivering equity of care to varied demographics. We will challenge conventional wisdom by debating the necessity of routine STI screening in asymptomatic individuals using PrEP, an area of contention with significant implications for resource allocation, patient management and antibiotic stewardship. Expert opinions will illuminate diverse perspectives and audience participation will enrich the discourse.

**Chairs: Anna Maria Geretti (Roma), Sandro Mattioli (Bologna)**

16.30 - 16.45 STI surveillance in Italy: what's hidden under the carpet?

Barbara Suligoj, Roma

16.45 - 17.00 Standards of STI care: what good will look like  
"Hosted by STI, a BMJ journal"

Valeska Padovese, Malta

Debate: do we need to reduce STI screening in asymptomatic  
PrEP users?

17.00 - 17.07 The argument against

Silvia Nozza, Milano

17.07 - 17.14 The argument for

Nicolò Girometti, London UK

17.14 - 17.30 Q&A and take away points

Moderators:  
Anna Maria Geretti, Roma  
Sandro Mattioli, Bologna

**16:30 - 17:30**

**Aula 5**

>>> Oral Communications

### The complexities of HIV infection

**Chairs: Antonella d'Arminio Monforte (Milano), Andrea Gori (Milano)**

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**16.30 - 16.35 Introduction**

*Antonella d'Arminio Monforte,  
Milano  
Andrea Gori, Milano*

**16.35 - 16.45 All-cause mortality in people diagnosed with HIV in Italy in  
ID 184 OC 26 1995-2019: data from the ICONA cohort**

*Andrea Giacomelli, Milano*

**16.47 - 16.57 Burden of advanced HIV disease (AHD) among antiretroviral  
ID 273 OC 27 therapy (ART)-experienced persons with HIV (PWH) in Italy  
over the past 20 years**

*Annalisa Mondì, Roma*

**16.59 - 17.09 Kidney transplantation in people living with HIV: ten-year  
ID 284 OC 28 experience in Modena**

*Adriana Cervo, Modena*

**17.11 - 17.21 HIV advanced naive: the forgotten test  
ID 364 OC 29**

*Arianna Narducci, Foggia*

**17.23 - 17.30 Conclusion**

*Antonella d'Arminio Monforte,  
Milano  
Andrea Gori, Milano*

**16:30 - 17:30**

**Aula 6**


>>> Oral Communications

**Immunological features in people living with HIV**

**Chairs: Giuseppe Nunnari (Messina), Daria Lucia Trabattoni (Milano)**



19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE



Promosso da  
SIMIT  
Società Italiana di Microbiologia e Immunologia

www.icar2024.it



**16.30 - 16.35 Introduction**

*Giuseppe Nunnari, Messina  
Daria Lucia Trabattoni, Milano*

**16.35 - 16.45 Scant effect of cART on mucosal immune cells during acute HIV infection**  
ID 147 OC 30

*Camilla Tincati, Milano*

**16.47 - 16.57 Viro-immunological reservoirs characterization in PBMCs and GALT in individuals on dual and triple-ART regimens**  
ID 430 OC 31

*Sohaib Khan, Roma*

**16.59 - 17.09 Oxidative stress in virologically suppressed people with HIV: Is dual antiretroviral therapy associated with a more favourable profile?**  
ID 43 OC 32

*Francesca Lombardi, Roma*

**17.11 - 17.21 Characterization of specific T-cell responses to a Three-Doses nonavalent HPV Vaccine Schedule in PLWH on ART**  
ID 367 OC 33

*Eeva Tortellini, Roma*

**17.23 - 17.30 Conclusion**

*Giuseppe Nunnari, Messina  
Daria Lucia Trabattoni, Milano*

**16:30 - 17:30**

**Aula 7**

>>> Short Communications

**COVID-19 Unmasked: role of immunity and early treatment**

**Chairs: Alessandra Bandera (Milano), Vincenzo Esposito (Napoli)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**16.30 - 16.33 Introduction**

*Alessandra Bandera, Milano  
Vincenzo Esposito, Napoli*

**16.33 - 16.40 SARS-CoV-2 vaccination influence in development of Long-  
ID 180 SC 31 COVID clinical phenotypes**

*Michele Antonacci, Roma*

**16.42 - 16.49 A machine learning tool to operationalize Intrinsic Capacity in  
ID 473 SC 32 predicting recovery from post-acute sequelae COVID-19**

*Jovana Milic, Modena*

**16.51 - 16.58 MicroRNAs in SARS-CoV-2 infection: a comparative analysis in  
ID 267 SC 33 immunocompromised versus non-immunocompromised patients**

*Chiara Siniscalchi, Napoli*

**17.00 - 17.07 Impact of Early Antiviral Therapy on Time to SARS-CoV-2  
ID 275 SC 34 Clearance in High-Risk COVID-19 Patients: A Propensity Score Matching Study**

*Marta Colaneri, Milano*

**17.09 - 17.16 Efficacy and safety of Sotrovimab vs oral antivirals in Omicron  
ID 294 SC 35 waves: a retrospective analysis**

*Chiara Cacace, Napoli*

**17.18 - 17.25 SARS-CoV-2-specific neutralizing activity and cytokine profile  
ID 222 SC 36 in newborns of vaccinated and/or infected and vaccinated mothers**

*Claudia Vanetti, Milano*

**17.27 - 17.30 Conclusion**

*Alessandra Bandera, Milano  
Vincenzo Esposito, Napoli*

**17:35 - 18:30**

**Aula Lazzati**

>>> Special Session

**ICAR-CROI Awards 2024**

This session is devoted to Young Italian Researchers - under 40 - who had an abstract accepted at CROI 2024. The following prizes will be announced and awarded: two prizes for the best Clinical and Basic science abstracts.

**Chairs: Roberto Cauda (Roma), Massimo Galli (Milano), Adriano Lazzarin (Milano)**

**17.35 - 17.45 Introduction**

*Roberto Cauda, Roma*

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research


Promosso da  
**SIMIT**  
Società Italiana di  
Malattie Infettive e  
Tropicali

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

17.45 - 18.00	<b>The Italian Young Investigators who had an abstract accepted at CROI 2024</b>	<i>Massimo Galli, Milano Adriano Lazzarin, Milano</i>
	• Immune responses to an original/BA.4-5 Bivalent Booster of SARS-CoV-2 mRNA vaccine in PWH on ART	<i>Matteo Augello, Milano</i>
	• A matter of time: factors associated with delayed nPEP initiation	<i>Nicholas Brian Bana, Milano</i>
	• Evaluation of the performance of different high resolution Anoscopy triage strategies in MSM LWH	<i>Eugenio Nelson Cavallari, Roma</i>
	• Prevalence and resistance profiles of "unusual" HCV subtypes in Italy	<i>Collins Ambe Chenwi, Roma</i>
	• Intrahepatic HDV activity is fueled by integrated HBV DNA-derived HBs independently from CccDNA size	<i>Stefano D'Anna, Roma</i>
	• MPXV replication induces an IFN response and is suppressed by IFN- $\gamma$	<i>Alessandra D'Auria, Roma</i>
	• SARS-CoV-2 infection and hospitalization in immunocompromised children: a population-based study	<i>Costanza Di Chiara, Padova</i>
	• Real-life experience on the use of Remdesivir: a propensity score matched analysis	<i>Francesco Di Gennaro, Bari</i>
	• Antiretrovirals drug concentrations in post-mortem tissues for different body compartments: preliminary results from the Last Gift project	<i>Micol Ferrara, Torino</i>
	• Synergistic effects of HIV, HPV, and Polyomaviruses on interferon response in male anal mucosa	<i>Matteo Fracella, Roma</i>
	• SARS-CoV-2 natural infection elicits cross-reactive immunity to OC43	<i>Micaela Garziano, Milano</i>
	• Jarisch-Herxheimer reaction in patients with syphilis with or without prior antibiotic prophylaxis	<i>Samuel Lazzarin, Milano</i>
	• Outcome of a multidimensional intervention for insomnia in a Cohort of people living with HIV	<i>Maria Mazzitelli, Padova</i>



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY



- Predictors of Mpox duration and severity in the Italian multicenter mpox ICONA Cohort  
 • Pooled analysis of randomized trials comparing drug efficacy for early COVID-19 during omicron waves  
 • Predictors of failure to COVID-19 early therapies and drugs efficacy comparison by emulation trial

*Valentina Mazzotta, Roma*

---

- Transaminase elevations among patients with occult HBV infection on two-drug antiretroviral regimens

*Luca Mezzadri, Monza*

---

- Plausibility of sexual behavior changes and role of vaccination in Mpox outbreak control among MSM

*Davide Moschese, Milano*

---

- Lymphogranuloma venereum among men who have sex with men: 7 versus 21 days Doxycycline effectiveness

*Angelo Roberto Raccagni, Milano*

---

- Lipidome composition and weight changes at 48week 3TC-DTG and FTC/TAF/BIC: data of the ICONA Cohort

*Roberta Rovito, Milano*

---

- A model to eliminate viral Hepatitis infection in migrants: a prospective Study in Southern Italy

*Antonio Russo, Napoli*

---

- Seroprevalence of Mpox IgG antibodies in a Cohort of PLWH in Rome, during the 2022 outbreak

*Pierluigi Francesco Salvo, Roma*

---

- ERAPs control in vitro and ex-vivo SARS-CoV-2 infection by triggering antiviral immune response

*Irma Saulle, Milano*

---

- High plasma GFAP in older PWH with low Nadir CD4 supports legacy brain injury and reactive gliosis

*Martina Strano, Milano*

---

- Exacerbation of the RSV infectivity by SARS-CoV-2 in an in-vitro Co-Infection cellular model

*Claudia Vanetti, Milano*

---

- 18.00 - 18.30 ICAR-CROI Awards for the best Clinical and Basic science abstract 2024


*Roberto Cauda, Roma  
Massimo Galli, Milano  
Adriano Lazzarin, Milano*

**18:30 - 19:30****Aula 6**

&gt;&gt;&gt; Parallel Session

**Screening HIV all'interno del Pronto Soccorso (un progetto congiunto SIMIT-SIMEU)****Chairs: Massimo Andreoni (Roma), Fabio De Iaco (Torino)**

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE  
**ICAR**  
Italian Conference on AIDS and  
Antiviral Research



www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

18.30 - 18.45 **Saluti e introduzione**

*Massimo Andreoni, Roma  
Fabio De Iaco, Torino*

18.45 - 19.10 **Lo screening HIV all'interno del pronto soccorso**

*Referenti SIMEU:  
Andrea Fabbri, Napoli  
Beniamino Susi, Roma  
Referenti SIMIT:  
Francesco Maria Fusco, Napoli  
Giulia Carla Marchetti, Milano  
Camilla Tincati, Milano*

19.10 - 19.20 **Discussione**

19.20 - 19.30 **Conclusioni**

*Massimo Andreoni, Roma  
Fabio De Iaco, Torino*

**18:30 - 19:30**

**Aula 7**

>>> Parallel Session

### Meeting Prestigio

**Chair: Antonella Castagna (Milano)**

**18:30 - 19:30**

**Sala Germania**


>>> Parallel Session

### Sierocoinvolto

Conigli Bianchi e PrEP in Italia presentano "Sierocoinvolto, la rivoluzione sessuale riparte dall'HIV" assieme alle persone che hanno scritto il libro. Un viaggio attraverso emozionanti racconti autobiografici che testimoniano quanto l'HIV sia molto di più che un tema meramente scientifico.

**Chair: Silvia Bellucci (Roma)**

**Con la partecipazione di Antonella Cingolani e Antonio di Biagio**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY



## Friday, June 21

**08:00 - 09:00**
**Sala Germania**

&gt;&gt;&gt; Parallel Session

### Investigator Meeting of EDOLAS study

**08.00 - 08.15** Introduzione

*Andrea Antinori, Roma  
Franco Maggiolo, Fabro TR*
**08.15 - 08.25** Protocollo EDOLAS

*Roberta Gagliardini, Roma*
**08.25 - 08.40** Status centri e status arruolamenti

*Roberta Gagliardini, Roma*
**08.40 - 08.55** Discussione

**08.55 - 09.00** Conclusioni

*Andrea Antinori, Roma*
**09:00 - 10:00**
**Plenary-Aula Lazzati**

&gt;&gt;&gt; Keynote Lectures

**Chairs: Andrea Cossarizza (Modena), Annalisa Saracino (Bari)**
**09.00 - 09.30** New emerging and re-emerging viral infection in Europe and in Italy

*Eskild Petersen, Arthus*

Infectious diseases are dynamic. Outbreaks of known diseases continue to surprise us and new diseases appear, often from zoonotic reservoirs (H5N1 influenza, SARS, Nipah, MERS, SFTS, H7N9 influenza, arboviruses), and some became endemic. The lecture will address new emerging and re-emerging infection in Europe and in Italy.

**09.30 - 10.00** Insights into SARS-CoV-2: an immunological journey throughout imprinting, vaccine responses and risk of subsequent infections

*Alessandro Sette, La Jolla*

Immunological memory is the basis of protective immunity provided by vaccines and previous SARS-CoV-2 infections. Understanding the diverse mechanisms of developing immunological memory against SARS-CoV-2 could help to define post-infection immunity and address appropriate vaccination strategies. This lecture gives a deep insight into the multiple branches of the adaptive immune system (CD4, CD8 and B cells and antibodies) during SARS-CoV-2 infection.



**Presidenza del Congresso**  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**10:05 - 11:05**

**Aula Lazzati**

>>> Symposium

*With an unrestricted educational grant from ViiV Healthcare*

## From RCT to clinical practice: evidences in treatment and prevention of LA regimens

Antiretroviral therapy is evolving toward longer-duration administrations that can improve adherence and quality of life in PWH. The first fully LA-comprehensive regimen for the treatment of HIV infection in virologically controlled patients, consisting of cabotegravir and rilpivirine, has recently become available; EMA also recently approved cabotegravir for the prevention of HIV infection for people at risk. The objective of this symposium will be to summarize the development of this regimen, the molecule, and the impact of the treatment in the Italian reality and the possible impact of the drug in the prevention setting.

**Chairs: Andrea Gori (Milano), Carlo Federico Perno (Roma)**

<b>10.05 - 10.20</b>	<b>Introduction: new frontiers in cabotegravir development</b>	<i>John Thornhill, London UK</i>
<b>10.20 - 10.30</b>	<b>Implementation of LA regimens in Italy: data from the ICONA Cohort</b>	<i>Antonella Cingolani, Roma</i>
<b>10.30 - 10.45</b>	<b>Real World Evidence of effectiveness of LA regimens</b>	<i>Camilla Muccini, Milano Lucia Taramasso, Genova</i>
<b>10.45 - 10.55</b>	<b>Perspectives in PrEP LA regimens</b>	<i>Valentina Mazzotta, Roma</i>
<b>10.55 - 11.05</b>	<b>Discussion</b>	

**10:05 - 11:05**

**Aula 5**


>>> Expert Meeting

## Vaccination in immunocompromised people: let's protect the vulnerable

The immunocompromised patient is among the ones at greater risk of infections, and therefore vaccinations become fundamental for its management. Among vaccinations recommended for immunocompromised patients the main are against: herpes zoster, pneumococcus, gonorrhoea and meningococcus. In this process, the infectious disease specialist has a central role for both the patient and the other specialists involved. One of the strategic objectives of the Global Vaccine Action Plan is for the benefits of immunisation to be equitably extended to all people. This approach encompasses special groups at increased risk of vaccine-preventable diseases, such as those with chronic and immune-compromising medical conditions or at increased risk of disease due to immunosenescence. Despite the remarkable success of global vaccination programmes, vulnerable populations (VPs) — who are particularly susceptible to infectious diseases — are often undervaccinated and are at much higher risk of recurrence, complications than the general population. There is concern that the immunosuppressive medications used in these patients place them at even greater risk and therefore vaccinations such as herpes zoster, VRS, pneumococcus and meningococcus become fundamental in these population.

**Chairs: Massimo Andreoni (Roma), Claudio Maria Mastroianni (Roma)**

**Discussants: Ivan Gentile (Napoli), Loredana Sarmati (Roma), Antonietta Spadea (Roma)**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**10:05 - 11:05****Aula 6**

&gt;&gt;&gt; Oral Communications

**Tailored approaches to antiretroviral therapy****Chairs: Stefano Bonora (Torino), Antonio Cascio (Palermo)****10.05 - 10.10 Introduction***Stefano Bonora, Milano  
Antonio Cascio, Palermo*

**10.10 - 10.20 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load  $\leq 50$  copies/mL** *Alessandro Cozzi-Lepri, London*  
ID 269 OC 34

**10.22 - 10.32 Cumulative risk of discontinuation of modern first-line ART by reason for stopping and type of ART initiated: findings from the ICONA cohort** *Mariacristina Poliseno, Bari*  
ID 234 OC 35

**10.34 - 10.44 CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low level viremia (LLV) up to Week 192 with Fostemsavir (FTR) based regimens in individuals with multidrug-resistant (MDR) HIV-1** *Vincenzo Spagnuolo, Milano*  
ID 159 OC 36

**10.46 - 10.56 Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine** *Francesca Alberton, Milano*  
ID 213 OC 37

**10.58 - 11.05 Conclusion***Stefano Bonora, Milano  
Antonio Cascio, Palermo***10:30 - 11:30****Aula 7**

&gt;&gt;&gt; Short Communications

**Hot topics in the epidemiology of relevant chronic and respiratory viral infections****Chairs: Giulia Valeria Calvino (Roma), Giuseppe Lapadula (Monza)**





**Presidenza del Congresso**  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

### 10.30 - 10.33 Introduction

*Giulia Valeria Calvino, Roma*  
*Giuseppe Lapadula, Monza*

### 10.33 - 10.40 HIV infection among migrants present in Italy from 2012 to 2022: incidence and characteristics

ID 21 SC 37

*Vincenza Regine, Roma*

### 10.42 - 10.49 High rates of anal polyomaviruses and HPV co-infection among people living with HIV

ID 191 SC 38

*Matteo Fracella, Roma*

### 10.51 - 10.58 Trends of toxoplasma antibody prevalence in naive people living with HIV in Italy. Data from the ICONA cohort

ID 289 SC 39

*Giorgio Bozzi, Milano*

### 11.00 - 11.07 Epidemiological evolution of Hepatitis C Virus infection and treatment outcomes in Tuscany (Italy): a comprehensive analysis spanning the direct-acting antiviral era and the impact of the COVID-19 pandemic

ID 120 SC 40

*Maria Paola Tramonti Fantozzi, Pisa*

### 11.09 - 11.16 Cases of untyped Influenza A virus in northern Italy

ID 108 SC 41

*Irene Giberti, Genova*

### 11.18 - 11.25 Respiratory syncytial virus viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?

ID 336 SC 42

*Rossana Scutari, Roma*

### 11.27 - 11.30 Conclusion

*Giulia Valeria Calvino, Roma*  
*Giuseppe Lapadula, Monza*

## 11:10 - 12:35

**Aula Lazzati**

### >>> Symposium

### Deep into HIV treatment Guidelines

Advances in antiretroviral therapy have changed the life expectancy of PWH which is now almost comparable to that of HIV-negative individuals. Following a long-life therapy involves facing various challenges, such as choosing the initial therapy, optimizing it if necessary, and developing alternative regimens in case of treatment failure ; this is made possible by the availability of new drugs with different mechanisms of action and different modes of administration. The aim of this symposium is to provide the most up-to-date information on current guidelines for the antiretroviral treatment and give insights into ART strategies and drugs. Discussion and comparison between members/authorities of international HIV treatment guideline and (young) physicians who daily address these issues will lead to this achievement.

**Chairs: Antonella Castagna (Milano), Annamaria Cattelan (Padova)**

**Discussants: Roy M. Gulick (New York USA), Esteban Martinez (Barcelona ES)**



**Presidenza del Congresso**  
 A. Cingolani, Roma  
 A. Di Biagio, Genova  
 M. Farinella, Roma  
 G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**11.10 - 11.15 Introduction**

*Antonella Castagna, Milano  
 Annamaria Cattelan, Padova*

**Critical issues and solutions within the DHHS and EACS guidelines. Focus on:**

**11.15 - 11.25 Initial antiretroviral therapy**

*Andrea Giacomelli, Milano*

**11.25 - 11.35 Discussion**

*Roy M. Gulick, New York USA  
 Esteban Martinez, Barcelona ES*

**11.35 - 11.45 Optimization of antiretroviral therapy**

*Alberto Borghetti, Pisa*

**11.45 - 11.55 Discussion**

*Roy M. Gulick, New York USA  
 Esteban Martinez, Barcelona ES*

**11.55 - 12.05 Virological failure**

*Vincenzo Spagnuolo, Milano*

**12.05 - 12.15 Discussion**

*Roy M. Gulick, New York USA  
 Esteban Martinez, Barcelona ES*

**12.15 - 12.25 Antiretroviral therapy in pregnancy**

*Lucia Taramasso, Genova*

**12.25 - 12.35 Discussion**

*Roy M. Gulick, New York USA  
 Esteban Martinez, Barcelona ES*

**11:10 - 12:50****Aula Bausola**

&gt;&gt;&gt; Meet the Expert and Oral Communications

### **Critical clinical aspects underlining the control of viral hepatitis and emerging viral infections**

An estimated 130-170 million people worldwide are infected with the hepatitis C virus, and there are about 2.8 million new infections each year. In Italy, there are currently about 100 new cases (incidence) of acute hepatitis giving a clinically manifest form each year, while the percentage of the Italian population (prevalence) that has a persistent (chronic) infection is not precisely known. It is believed, however, that this percentage is higher than 3 percent in people born before 1950 and increases progressively with age, but is considerably lower in younger generations. Moreover, the prevalence of the disease is higher in southern Italy and the islands than in central and northern regions. Due to the possibility of using new drugs that are extremely effective against HCV, WHO has launched a project to eradicate HCV infection by 2030. Italy is currently engaged with a screening campaign for the emergence of the undeclared in order to reach the goal indicated by WHO.

Summer 2023 saw as many as 4 introductions of different Dengue viral genotypes in our country: 3 small outbreaks in the Lazio region and one in the Lombardy region. The identification for the first time of dozens of dengue cases in a major European metropolitan city such as Rome deserves reflections in terms of training of frontline health workers, availability of diagnostic tests including rapid ones, early identification of cases, and integration with territorial and regional epidemiological prevention services, municipal services for pest control, and regional zooprophyllactic institutes for other vector control measures. Last but not least, the current epidemic in Central and South America is surprising in size and persistence of the wide circulation of Dengue virus in two consecutive years: several factors could explain the phenomenon, which, however, remains unexpected.

**Chairs: Giampiero Carosi (Brescia), Carlo Torti (Roma)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

<b>11.10 - 11.25</b>	<b>Programs of microelimination of HCV infection: which setting and who to reach?</b>	<i>Massimo Andreoni, Roma</i>
<b>11.25 - 11.30</b>	<b>Discussion</b>	
<b>11.30 - 11.45</b>	<b>Recent progress in understanding dengue</b>	<i>Emanuele Nicastrì, Roma</i>
<b>11.45 - 11.50</b>	<b>Discussion</b>	
<b>11.50 - 11.55</b>	<b>Oral Communications introduction</b>	<i>Giampiero Carosi, Brescia Carlo Torti, Roma</i>
<b>11.55 - 12.05</b> ID 240 OC 38	<b>Persistent HBV cryptic activity is frequently revealed among anti-HBc positive/HBsAg negative people living with HIV infection during HBV-active ART and can jeopardize the full control of HIV replication</b>	<i>Lorenzo Piermatteo, Roma</i>
<b>12.07 - 12.17</b> ID 324 OC 39	<b>Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV</b>	<i>Alessia Magnapera, Roma</i>
<b>12.19 - 12.29</b> ID 418 OC 40	<b>Investigating seroprevalence of IgG against Dengue virus (DENV) in a cohort of people with HIV (PLWH) in a non-endemic country after an autochthonous outbreak: are we ready for next season?</b>	<i>Pierluigi Francesco Salvo, Roma</i>
<b>12.31 - 12.41</b> ID 61 OC 41	<b>Viral Respiratory Infections in Patients with Haematological Diseases over 10 Years: a single-center Experience</b>	<i>Patrizia Bono, Milano</i>
<b>12.43 - 12.50</b>	<b>Conclusion</b>	<i>Giampiero Carosi, Brescia Carlo Torti, Roma</i>



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**11:10 - 12:10**

**Aula 5**

>>> Special Session

### Vaccines Pipeline: a glimpse of the future

An open discussion between researchers and R&D representatives of pharmaceutical companies that aims to outline and shape the future of vaccines development in the next decade.

**Chairs: Giulia Carla Marchetti (Milano), Maurizio Zazzi (Siena)**

**11.10 - 11.20 Introduction: "Vaccine development, regulatory aspects, and marketing authorisation"**

*Adriana Ammassari, Roma*

**11.20 - 11.30 Ennio De Gregorio**, Head of Research and Development Center Vaccines Italy at GSK

**11.30 - 11.40 Mel Kohn**, Executive Director Medical Affairs at MSD

**11.40 - 11.50 Alessandro Zollo**, Medical Head Vaccines & Immunotherapy Italy at Astrazeneca

**11.50 - 12.10 Q&A and Discussion**

**11:10 - 12:10**

**Aula 6**

>>> Oral Communications

### Awareness in Sexual Health: U=U and prevention

**Chairs: Salvatore Cecere (Bologna), Benedetto Maurizio Celesia (Catania)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**11.10 - 11.15 Introduction**

*Salvatore Cecere, Bologna  
Benedetto Maurizio Celesia,  
Catania*

**11.15 - 11.25 Information and Misinformation on HIV and the Narration of the Evidence U=U: a mixed method analysis on social media in Italy**  
ID 441 OC 42

*Virginia Casigliani, Pisa*

**11.25 - 11.35 "U=U impossibile sbagliare" awareness campaign: impact assessment among PLWH**  
ID 277 OC 43

*Antonella Cingolani, Roma*

**11.35 - 11.39 Discussion**

**11.39 - 11.49 Loss of "U=U status" in Women with HIV: insights into possible reasons for a higher risk compared to Men**  
ID 51 OC 44

*Rosa Fontana Del Vecchio,  
Siracusa*

**11.49 - 11.59 DoxyPEP is already used in two community-based centers in Bologna and Rome. An explorative survey**  
ID 111 OC 45

*Marco Stizioli, Montichiari*

**11.59 - 12.03 Discussion**

**12.03 - 12.10 Conclusion**

*Salvatore Cecere, Bologna  
Benedetto Maurizio Celesia,  
Catania*

**11:35 - 12:35**

**Aula 7**

>>> Themed Discussion

**Because the virus matters**

**Chairs: Bianca Bruzzone (Genova), Annalisa Mondì (Roma)**

**11.35 - 11.38 Introduction***Bianca Bruzzone, Genova  
Annalisa Mondì, Roma***11.38 - 11.45 Viral Blips among People Living with HIV following recommended vaccines** *Benedetta Trentacapilli, Milano*  
ID 116 TD 11**11.45 - 11.52 Clinical presentation of newly diagnosed PWH in the last four-years period post COVID-19 pandemic, in a single center in Rome: a retrospective observational study** *Andrea Carbone, Roma*  
ID 472 TD 12**11.52 - 11.59 Clinical and Immunovirological Features of Potential Post Treatment HIV Controllers** *Stefano Rapino, Brescia*  
ID 158 TD 13**11.59 - 12.06 Two-drugs regimens did not influence HIV-1 DNA in people living with HIV** *Alice Nava, Milano*  
ID 90 TD 14**12.06 - 12.13 Virological performance and resistance-associated mutations in people living with HIV switching to bicitgravir/emtricitabine/tenofovir alafenamide in the Italian ARCA cohort: the BIC-BARRIER Study** *Laura Pezzati, Legnano*  
ID 247 TD 15**12.13 - 12.35 Discussion****12:35 - 13:35****Aula 5****>>> Expert Meeting***With an unrestricted educational grant from ViiV Healthcare***The unheard voices. Perspectives of "difficult" patients**

In recent years, antiretroviral therapies have become extremely effective with a good tolerability profile. Much attention is now paid to the impact of the disease and drugs on the quality of life of people living with HIV, and increasingly PROs are part of evaluations of a treatment regimen. There are particularly complex situations - HTE, frail populations - where the quality aspect may sometimes not be the focus by prioritizing efficacy. In this symposium we want to draw attention to the importance of using PROs in these populations as well, considering the availability of new treatments.

**Chairs: Mario Cascio (Milano), Giovanni Guaraldi (Modena)****12.35 - 12.50 From collection of PROs to identification of novel outcomes** *Antonella Cingolani, Roma***12.50 - 13.05 Evidence and perspective from patients engagement studies** *Ana Milinkovic, London UK*

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

2024



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

13.05 - 13.20 **HTE patients: which outcomes to consider from patient' perspective?** *Antonella Castagna, Milano*

13.20 - 13.35 **Discussion**

**12:40 - 13:40**

**Aula Lazzati**

>>> Symposium

## HIV, lights and shadows on new treatment strategies: focus on new drug classes

Antiretroviral therapy has changed the life expectancy of people with HIV infection (PWH) and drastically improved their quality of life. New drugs for remaining needs are flourishing and progressively reaching the clinical arena. Nevertheless, there are still many pending issues related to their management and efficacy. One of the key topics is the definition of their resistance profile, in vitro and in vivo, in different groups of people with HIV, either naive or drug-experienced; secondly, how to properly assess their pharmacological properties; thirdly, how to leverage new methodologies to determine drug resistance to these drugs in clinical practice. This symposium will shed light on these very important matters for the proper management of people with HIV.

**Chairs: Francesca Ceccherini Silberstein (Roma), Stefano Rusconi (Legnano MI)**

12.40 - 12.55 **In vitro and in vivo efficacy**

*Roberta Gagliardini, Roma*

12.55 - 13.00 **Discussion**

13.00 - 13.15 **Pharmacology**

*Antonio D'Avolio, Torino*

13.15 - 13.20 **Discussion**

13.20 - 13.35 **Resistance**

*Francesco Saladini, Siena*

13.35 - 13.40 **Discussion**

**12:55 - 13:55**

**Aula Bausola**

>>> Symposium

## New knowledge in chronic viral infections


New important evidences are available on some chronic viral infection. As regard HBV infection the use of new and different therapeutical targets may allow a functional cure of an infection that afflict millions of persons in the world. Recently, the introduction of bulevirtide and the study on other antiviral targets open new scenario in the management of HDV chronic hepatitis. Finally, it seems to be the time to introduce an antimicrobial stewardship strategy also for CMV infection.

**Chairs: Nicola Coppola (Napoli), Loredana Sarmati (Roma)**

12.55 - 13.10 **From virological suppression to HBV functional cure: is an achievable goal so far by the new drugs?** *Maurizia Rossana Brunetto, Pisa*



19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA



**Presidenza del Congresso**  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE  
**ICAR**  
Italian Conference on AIDS and  
Antiviral Research



www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**13.10 - 13.15 Discussion**

**13.15 - 13.30 HDV from pathogenesis to novel therapies**

*Massimo Puoti, Milano*

**13.30 - 13.35 Discussion**

**13.35 - 13.50 Is this the time to introduce CMV stewardship?**

*Giuseppe Gentile, Roma*

**13.50 - 13.55 Discussion**

**13:00 - 13:50**

**Aula 7**

>>> Short Communications

**Bridging innate and adaptive immunity in viral infections**

**Chairs: Saverio Parisi (Padova), Ilaria Vicenti (Siena)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**13.00 - 13.03 Introduction**

*Saverio Parisi, Padova  
Ilaria Vicenti, Siena*

**13.03 - 13.10 Modulation of Cytomegalovirus (CMV) T cells response in PLWH after switching to long-acting (LA) cabotegravir plus rilpivirine**

ID 362 SC 43

*Mariasilvia Guardiani, Roma*

**13.12 - 13.19 T cells profile in persons living with HIV (PLWH) with Progressive Multifocal Leucoencefalopathy (PML)**

ID 356 SC 44

*Eleonora Cimini, Roma*

**13.21 - 13.28 Comparing T-Spot and In-House IGRA for Assessing SARS-CoV -2-Specific Cell-Mediated Immunity**

ID 332 SC 45

*Livia Benedetti, Roma*

**13.30 - 13.37 Vδ2 T cells effector response in PLWH and PLWoh up to three months from mpox infection**

ID 117 SC 46

*Eleonora Cimini, Roma*

**13.39 - 13.46 Are neutralizing autoantibodies to type I interferon novel disease determinants in people living with HIV?**

ID 132 SC 47

*Ginevra Bugani, Roma*

**13.48 - 13.50 Conclusion**

*Saverio Parisi, Padova  
Ilaria Vicenti, Siena*

**13:20 - 14:20**

**Sala Germania**

>>> Parallel Session

**Meeting Community U=U Conclusione progetto**

**Chair: Filippo Schloesser (Roma)**

**13:40 - 14:50****Aula 5**

&gt;&gt;&gt; Meet the Expert DREAM and Themed Discussion

**Crossing borders and fighting inequalities**

Since its beginning in 2002, DREAM has been driving significant advancements in the fight against AIDS in Africa:

- In 2002, the introduction of ART with free access in countries where there was nothing
  - In 2004, anticipation of the start of therapy compared to existing protocols, triple therapy instead of monotherapy for pregnant women
  - Since 2006, routine monitoring of viral load
- Currently, DREAM is present in 10 African countries with centers of excellence and national reference laboratories, with 50 active care centers and day hospitals, and 28 molecular biology laboratories. Today, access to therapy is a reality even in the poorest countries, but we are working to reach those who have been left behind: children (especially in West Africa), girls and young women, who are among the groups with the highest incidence; the male population, which does not have easy access to health facilities. Alongside this, there are new challenges:
- non-communicable diseases associated with HIV infection
  - the emergence of strains resistant to even the new first-line treatments
  - TB co-infection posing problems of sometimes complex diagnosis,
  - HPV infection in HIV-positive women, molecular diagnosis of HPV, and vaccination

**Chairs: Francesco Castelli (Brescia), Giuliano Rizzardini (Milano)****13.40 - 13.55 DREAM after 20 years: where we are and who still need to be reached***Giovanni Guidotti, Roma***13.55 - 14.00 Discussion****14.00 - 14.07 Active close contact investigation of tuberculosis through Computer-Aided Detection and stool Xpert MTB/RIF among people living in Oromia region, Ethiopia: a preliminary results**

ID 190 TD 16

*Giacomo Guido, Bari***14.07 - 14.14 The impact of COVID-19 on the Virological Suppression in People Living with HIV Followed up at the Hospital Divina Providência in Luanda, Angola**

ID 264 TD 17

*Andrea Calcagno, Torino***14.14 - 14.21 Trends in HIV-related stigma and gender inequality indicators: findings from a peer-based intervention prevention program in rural northern Uganda**

ID 323 TD 18

*Giulia Micheli, Roma***14.21 - 14.28 High In-hospital Mortality and Significant Prevalence of HIV among Patients Admitted to a Tuberculosis Ward at Divina Providência Hospital in Luanda - Angola, 2023**

ID 176 TD 19

*Ana Sofia Lopes Sucuma, Torino***14.28 - 14.50 Discussion**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**13:50 - 15:00**

**Aula Lazzati**

>>> Symposium

### Striving for an HIV cure: from post-treatment control to a natural cure

The symposium is meant to address different topics concerning the delicate equilibrium between protective and pathogenetic role of the immune system over HIV infection in cohorts exhibiting a peculiar relation with the virus. In particular, a comprehensive review on the correlates of protection characterizing the immune response in cohorts of HIV-exposed uninfected children born from HIV-infected mothers and elite controllers will be provided. The possibility of reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control will be harnessed as well. The critical revision of all these information will be essential to dissect and identify new potential targets/pathways to be exploited in the setting up of innovative therapeutic approaches.

**Chairs: Chiara Agrati (Roma), Camilla Tincati (Milano)**

**13.50 - 14.05 Immunological clues in HIV exposed uninfected children born from HIV-infected mothers** *Domenico Mavilio, Rozzano MI*

**14.05 - 14.20 Exceptional elite controllers: do they truly exist?** *Mario Salvatore Clerici, Milano*

**14.20 - 14.25 Discussion**

**14.25 - 14.40 CD8+ T-cell reprogramming and natural control of HIV** *Caroline Petitdemange, Paris FR*

**14.40 - 14.55 bNAbs for HIV management and cure** *Giulia Carla Marchetti, Milano*

**14.55 - 15.00 Discussion**


**14:00 - 15:00**

**Aula Bausola**

>>> Oral Communications

### A tale of two pandemics: molecular insights on SARS-CoV-2 and HIV

**Chairs: Emanuele Nicastrì (Roma), Maria Santoro (Roma)**



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**14.00 - 14.05 Introduction***Emanuele Nicastri, Roma  
Maria Santoro, Roma***14.05 - 14.15 Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy during the Omicron era**

ID 49 OC 46

*Annalisa Bergna, Milano***14.15 - 14.25 Genomic characterization of SARS-CoV-2 Omicron variants and clinical presentation in immunocompromised and non-immunocompromised adult people**

ID 468 OC 47

*Maria Concetta Bellocchi, Roma***14.25 - 14.29 Discussion****14.29 - 14.39 Analysis of chromosome integration sites of HIV-1 DNA in PBMC of PWH showing plasma HIV-1 RNA detected only by the LTR target with Aptima HIV-1 Quant Dx assay**

ID 44 OC 48

*Giuseppe Sberna, Roma***14.39 - 14.49 Post-translational HIV-1 integrase modification sites might be affected by complex and prolonged treatment history associated with multidrug resistance: a proof of concept study from the PRESTIGIO registry**

ID 128 OC 49

*Daniele Armenia, Roma***14.49 - 14.53 Discussion****14.53 - 15.00 Conclusion***Emanuele Nicastri, Roma  
Maria Santoro, Roma***14:00 - 15:00****Aula 6**

&gt;&gt;&gt; Oral Communications

**PrEP and prevention strategies****Chairs: Annalisa Saracino (Bari), Maria Stagnitta (Firenze)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**14.00 - 14.05 Introduction**

*Annalisa Saracino, Bari  
Maria Stagnitta, Firenze*

**14.05 - 14.15 Implementation of PrEP in Italy: results of PrIDE survey**

*Silvia Nozza, Milano*

ID 29 OC 50

**14.15 - 14.25 HIV pre-exposure prophylaxis (PrEP) efficacy, adherence and persistence in an Italian multicentric cohort: ItaPrEP study**

*Valentina Mazzotta, Roma*

ID 370 OC 51

**14.25 - 14.29 Discussion**

**14.29 - 14.39 Overcoming HPV vaccination barriers in target populations: the VACCINAMILANO experience**

*Federico Barone, Milano*

ID 342 OC 52

**14.39 - 14.49 HIV screening strategies in the Emergency department to reveal hidden infections**

*Andrea Santoro, Milano*

ID 249 OC 53

**14.49 - 14.53 Discussion**

**14.53 - 15.00 Conclusion**

*Annalisa Saracino, Bari  
Maria Stagnitta, Firenze*

**14:00 - 15:00**

**Aula 7**

>>> Oral Communications

**HIV associated comorbidities: matters of the heart**

**Chairs: Paolo Bonfanti (Monza), Paolo Maggi (Caserta)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**14.00 - 14.05 Introduction**

*Paolo Bonfanti, Monza  
Paolo Maggi, Caserta*

**14.05 - 14.15 Incidence of metabolic syndrome in people with HIV in Italy  
ID 335 OC 54 who started ART since 2008: data from the ICONA cohort**

*Elena Bruzzesi, Milano*

**14.17 - 14.27 Current and temporal exposure to integrase strand transfer  
ID 475 OC 55 inhibitors are not associated with hypertension or arterial  
stiffness in people with HIV**

*Matteo Mantovani, Modena*

**14.29 - 14.39 Metabolic and weight changes in people with HIV after  
ID 199 OC 56 switching to long-acting therapy with cabotegravir and  
rilpivirine: results from the SCohoLART study**

*Martina Bottanelli, Milano*

**14.41 - 14.51 Carotid intima media thickness (IMT) and statins prescriptions  
ID 339 OC 57 in the real life setting of the Archi Prevaleat cohort**

*Benedetto Maurizio Celesia,  
Catania*

**14.53 - 15.00 Conclusion**

*Paolo Bonfanti, Monza  
Paolo Maggi, Caserta*

**15:05 - 16:05**

***Aula Lazzati***

**>>> Meet the Expert in HIV**

The field of HIV medicine continues to be dynamic and innovative, even after more than 40 years since the first report of AIDS. This session is based on expert opinions which explore the latest developments in cutting-edge issues in HIV clinical management.

**Chairs: Paolo Maggi (Caserta), Ada Moznich (Milano)**

**15.05 - 15.20 HIV genotypic resistance test: clinical use for today and future  
challenges**

*Carlo Federico Perno, Roma*

**15.20 - 15.25 Discussion**

**15.25 - 15.40 Screening for non AIDS-related cancers: what we currently do  
and what we should do**

*Emanuela Vaccher, Aviano PN*

**15.40 - 15.45 Discussion**

**15.45 - 16.00 Do not forget the children: pioneering progress in pediatric  
HIV care...not only drugs**

*Vania Giacomet, Milano*



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

16.00 - 16.05 Discussion

**15:05 - 16:05**

**Aula Bausola**

>>> Oral Communications

**What is left to say on COVID-19 today?**

**Chairs: Marco Iannetta (Roma), Claudio Maria Mastroianni (Roma)**

15.05 - 15.10 Introduction

Marco Iannetta, Roma  
Claudio Maria Mastroianni,  
Roma

15.10-15.20 **Inflammatory milieu and specific T cells response after three months and one year from SARS-CoV-2 infection**

ID 254 OC 58

Eleonora Cimini, Roma

15.22 - 15.32 **Clinical features and impact on mortality of COVID-19 epidemics in patients with Non-Hodgkin lymphoma: long-term results from a tertiary center in Italy**

ID 420 OC 59

Emanuela Zappulo, Napoli

15.34 - 15.44 **Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active hematological disease undergoing off-label combined antiviral treatments**

ID 376 OC 60

Elena Matteini, Roma

15.46 - 15.56 **SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients**

ID 66 OC 61

Alessia Lai, Milano

15.58 - 16.05 Conclusion

Marco Iannetta, Roma  
Claudio Maria Mastroianni,  
Roma

**15:05 - 16:05**

**Aula 5**

>>> Oral Communications

**HIV associated comorbidities: pressing matters**

**Chairs: Sergio Carbonara (Bisceglie BT), Carmela Pinnetti (Roma)**





Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**15.05 - 15.10 Introduction**

*Sergio Carbonara, Bisceglie BT  
Carmela Pinnetti, Roma*

**15.10 - 15.20 Cancers in people living with HIV: an observational study in the cohort of Modena over 27 years**  
ID 371 OC 62

*Federica Prandini, Modena*

**15.22 - 15.32 CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL - a retrospective study of the MUSTHAL cohort**  
ID 280 OC 63

*Luisa Verga, Monza*

**15.34 - 15.44 Cognitive Performance in Older People with and without HIV in the GEPPCO Cohort**  
ID 265 OC 64

*Andrea Calcagno, Torino*

**15.46 - 15.56 Increasing prevalence of cognitive frailty in people living with HIV**  
ID 463 OC 65

*Jovana Milic, Modena*

**15.58 - 16.05 Conclusion**

*Sergio Carbonara, Bisceglie BT  
Carmela Pinnetti, Roma*

**15:05 - 16:05**

**Aula 6**

>>> Oral Communications

**Highlighting the diversity of people living with HIV**

**Chairs: Nicola Gianotti (Milano), Giovanni Mazzola (Caltanissetta)**

19-21 GIUGNO ROMA  
UNIVERSITÀ CATTOLICA  
DEL SACRO CUORE  
CENTRO CONGRESSI EUROPA

20  
24



Presidenza del Congresso

A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE

**ICAR**  
Italian Conference on AIDS and  
Antiviral Research

Promosso da  
SIMIT

www.icar2024.it



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**15.05 - 15.10 Introduction**

*Nicola Gianotti, Milano  
Giovanni Mazzola, Caltanissetta*

**15.10 - 15.20 Socio-demographic, clinical and therapeutic features of persons with HIV (PWH) currently in care in Italy: data from the ICONA cohort**

ID 130 OC 66

*Antonella d'Arminio Monforte,  
Milano*

**15.22 - 15.32 Low prevalence of optimal health-related quality of life in real-world data among people with HIV**

ID 405 OC 67

*Eduardo Gnoatto Perondi,  
Modena*

**15.34 - 15.44 African women living with HIV in Modena: far from fulfilling the gap**

ID 351 OC 68

*Federica Casari, Modena*

**15.46 - 15.56 Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori**

ID 461 OC 69

*Fabiana D'Aloia, Monza*

**15.58 - 16.05 Conclusion**

*Nicola Gianotti, Milano  
Giovanni Mazzola, Caltanissetta*

**15:05 - 16:05**

**Aula 7**

>>> Short Communications

**Stigma, awareness and education**

**Chairs: Francesco Mazzotta (Firenze), Laura Amelia Rachele Rancilio (Milano)**



Presidenza del Congresso  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**15.05 - 15.08 Introduction**

*Francesco Mazzotta, Firenze  
Laura Amelia Rachele Rancilio,  
Milano*

**15.08 - 15.15 Stigma on Screen: A Systematic Review of Cinema's HIV Narrative between 2016 and 2023**

ID 448 SC 48

*Agnese Colpani, Sassari*

**15.15 - 15.22 Minority stress and stigmatizing attitudes towards HIV: a cross-sectional study among MSM on PrEP, people living with HIV and people not living with HIV in Italy**

ID 197 SC 49

*Filippo Maria Nimbi, Bologna*

**15.22 - 15.26 Discussion**

**15.26 - 15.33 Experience of a community-based chemsex service: analysis of requests for help during the MDPV outbreak**

ID 72 SC 50

*Alessandra Bianchi, Milano*

**15.33 - 15.40 Chemsex knowledge and use among PrEP-users and PWH: a survey on the Milanese scene**

ID 316 SC 51

*Chiara Fusetti, Milano*

**15.40 - 15.44 Discussion**

**15.44 - 15.51 Comprehensive sexual health education in Italian secondary schools: preliminary results of the EduForIST national project**

ID 308 SC 52

*Alice Chinelli, Pisa*

**15.51 - 15.58 From information to test: the experience with high school students**

ID 325 SC 53

*Caterina Pellegris, Chioduno BG*

**15.58 - 16.02 Discussion**

**16.02 - 16.05 Conclusion**

*Francesco Mazzotta, Firenze  
Laura Amelia Rachele Rancilio,  
Milano*



**Presidenza del Congresso**  
A. Cingolani, Roma  
A. Di Biagio, Genova  
M. Farinella, Roma  
G. C. Marchetti, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

**16:10 - 16:30**

**Aula Lazzati**

>>> Special Session

## ICAR 2024 Awards and Closing remarks

ICAR and SIMIT support and reward the young excellences of Italian research with special prizes announced and awarded during this Session.

**Chairs: Massimo Andreoni (Roma) Antonella Cingolani (Roma), Antonio Di Biagio (Genova), Massimo Farinella (Roma), Franco Maggiolo (Fabro TR), Giulia Carla Marchetti (Milano)**

**ICAR 2024 Scientific Committee Awards: three prizes for the best Clinical, Basic science and Social sciences Abstracts**

*Franco Maggiolo, Fabro TR*

**SIMIT Special Awards: five prizes for the best Oral Communications in: Clinical HIV, Clinical Hepatitis Virus, Clinical SARS-CoV-2, Virology and Immunopathogenesis, Epidemiology and Social sciences**

*Massimo Andreoni, Roma*

**Special Award "Liliana del Cupolo": a prize for the best abstract in the field of Covid research in immunocompromised patients**

*Luigi Palla, Roma*

**Closing remarks announcement of ICAR 2025**

*Antonella Cingolani, Roma  
Antonio Di Biagio, Genova  
Massimo Farinella, Roma  
Giulia Carla Marchetti, Milano*